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SAINT LOUIS UNIVERSITY SCHOOL OF LAW

REGULATORY BARRIERS WHEN IMPLEMENTING E-PRESCRIBING
OF CONTROLLED SUBSTANCES: COULD MODEL LANGUAGE BE
THE SOLUTION?
Arguably nothing in our health-driven society permeates our everyday
life more than prescription drugs. Evidence of this comes from all avenues
of the prescription drug industry. Prescription drug direct-to-consumer
advertising is a multi-billion dollar market.1 Prescription drug revenues
totaled $300.3 billion dollars in 2009,2 and over 3.6 billion prescriptions
were dispensed.3 In light of these trends, it is no surprise that prescription
drug markets have been pushed to enhance delivery of medications from
the physician to patient. This article will focus on the relatively new realm of
electronic prescribing (“e-prescribing”) and the effect new Drug Enforcement
Agency (“DEA”) regulations4 will have on the practical implementation and
delivery of prescription medications.
Health information technology (“HIT”), electronic health records
(“EHR”), and e-prescribing are some of the flagships of healthcare reform.5
However, this isn’t a new phenomenon, EHR and e-prescribing initiatives
were implemented prior to the Clinton Administration within the Department
of Veterans Affairs’ health system, under the VIST-A program.6 VIST-A was

1. Theresa Howard, Push Is on to End Prescription Drug Ads Targeting Consumers, USA
Today, (Aug. 10, 2009, 11:10 AM), http://www.usatoday.com/money/advertising/adtrack/
2009-08-09-adtrack-prescription-drug-ads_N.htm.
2. Bill Berkrot, U.S. Prescription Drug Sales Hit $300 bln in 2009, REUTERS (Apr. 1, 2010,
1:34 PM), http://www.reuters.com/article/idUSTRE6303CU20100401.
3. Id.
4. See Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. 16,236
(proposed Mar. 31, 2010) (to be codified 21 C.F.R. at pts. 1300, 1304, 1306, 1311).
5. Daniel J. Gilman & James C. Cooper, There Is a Time to Keep Silent and a Time to
Speak, the Hard Part Is Knowing Which Is Which: Striking the Balance Between Privacy
Protection and the Flow of Health Care Information, 16 MICH. TELECOMM. & TECH. L. REV. 279,
280, 286, 288 (2010); see also ATTILA HERTELENDY ET AL., AM. HEALTH INFO. MGMT. ASS’N
(AHIMA), THE IMPLICATIONS OF HEALTH REFORM FOR HEALTH INFORMATION AND ELECTRONIC
HEALTH RECORD IMPLEMENTATION EFFORTS 1 (2010), available at http://perspectives.
ahima.org/PDF/Summer_2010/Implications_of_Health_Reform/Implications_of_Health_Re
form_on_Health_Information_final.pdf.
6. DOUGLAS GOLDSTEIN ET AL., Case Studies of VistA Implementation—United States and
International, in MEDICAL INFORMATICS 20/20, at 223, 226, 263 (2007), available at
http://www.jblearning.com/samples/0763739251/39251_CH09_223_284.pdf; see also
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the first major venture into the realm of EHR and e-prescribing, with the
computerization of Veteran Affairs’ health records.7 The reach of eprescribing is realizing new levels of integration with the promulgation of the
DEA’s new rule regulating e-prescribing of controlled substances.8 In March
2010, the DEA issued rules allowing e-prescribing of controlled substances
by all eligible, DEA-approved prescribers.9
I. E-PRESCRIBING EXAMINED
Before delving into the barriers of implementation and the potential
solutions, an examination of e-prescribing is warranted. E-prescribing is
defined as the transmission of prescription information through electronic
media between the prescriber, pharmacy, pharmacy benefit manager,
and/or health insurance plan.10 E-prescribing can be a two-way or a multistep transmission process.11 At its core, the eligible prescriber types a
prescription and sends it electronically (not by fax but via a closed secured
internet network) to a participating pharmacy.12 This information may go
directly to a pharmacy or it may first be redirected to a health plan or
managed care entity, such as a pharmacy benefit manager (“PBM”), for
insurance approval.13 Prescribers now have the option of sending electronic

June M. Sullivan, Recent Development and Future Trends in Electronic Medical and Personal
Health Records, HEALTH LAW., Jan. 2007, at 16, 17.
7. GOLDSTEIN ET AL., supra note 6, at 226, 227, 263.
8. Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. at 16,236.
9. The prescriber must meet all the formal requirements of the rule which includes a DEA
registration number in good standing with the DEA. Id. at 16,313.
10. EHEALTH INITIATIVE, A CLINICIAN’S GUIDE TO ELECTRONIC PRESCRIBING 1 (2008),
available at http://www.ama-assn.org/ama1/pub/upload/mm/472/electronic-e-prescrib
ing.pdf; see also NAT’L GOVERNORS ASS’N, ACCELERATING THE ADOPTION OF ELECTRONIC
PRESCRIBING 1 (2009), available at http://www.nga.org/files/live/sites/NGA/files/pdf/0907E
PRESCRIBING.PDF. The National Governors Association “electronic prescribing, or eprescribing, is computer-based electronic generation and transmission of a prescription.” Id.
at 2.
11. CAL. HEALTHCARE FOUND., E-PRESCRIBING 21 (2001), available at http://www.ch
cf.org/~/media/MEDIA%20LIBRARY%20Files/PDF/E/PDF%20EPrescribing.pdf.
12. Id. at 5; see also EHEALTH INITIATIVE, supra note 10, at 7, 25; see also SIEMENS, EPRESCRIBING: THE PATH TO PHYSICIAN ADOPTION OF HIT 6 (2009), available at http://www.medi
cal.siemens.com/siemens/en_INT/rg_marcom_FBAs/images/News/2010_01_HIT/EPrescribe
whitepaperA91339721v3.pdf.
13. CAL. HEALTHCARE FOUND., supra note 11, at 20. Many e-prescribing initiatives can
involve the insurance and formulary process to streamline insurance eligibility and coverage
problems. EHEALTH INITIATIVE, supra note 11, at 1, 4. However, it is common for the eprescribing relationship to be executed directly to retail pharmacies where a pharmacist and
pharmacy technician handle insurance processing, prior authorizations, or any other insurance
coverage/formulary issues. CAL. HEALTHCARE FOUND., supra note 11, at 20.
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prescriptions via wireless devices such as secure PDAs or cellular phones.14
Pharmacies in turn receive the information through their closed pharmacy
network and computer dispensing software that performs dispensing and
Providers have two general approaches for
screening functions.15
implementing e-prescribing in their environment either: (1) stand-alone
systems; or (2) integrated EHR systems with e-prescribing capabilities.16 The
latter involves a complete electronic overhaul of medical records including
medical charting, lab results, billing information, and e-prescribing.17 The
stand-alone system is a separate software program that allows physicians to
use traditional hospital resources in conjunction with a separate eprescribing software component.18
E-prescribing has been scientifically studied and statistically proven to
bring a number of benefits to the practice of medicine and pharmacy.19 Eprescribing reduces medication errors,20 and establishes a system to warn
physicians of drug interactions and contraindications.21 E-prescribing can
economize a physician’s practice if properly integrated into the workflow.22

14. CAL. HEALTHCARE FOUND., supra note 11, at 30.
15. Most major pharmacy software companies include e-prescribing software that
integrates into an existing pharmacy system. Surescripts Certified Pharmacy Software,
SURESCRIPTS, http://www.surescripts.com/connect-to-surescripts/pharmacy-software.aspx (last
visited Nov. 8, 2011).
16. EHEALTH INITIATIVE, supra note 10, at 2.
17. Id.
18. Id.
19. Gordon D. Schiff & T. Donald Rucker, Computerized Prescribing: Building the
Electronic Infrastructure for Better Medication Usage, 279 JAMA 1024, 1024 (1998).
“According to the Center for Information Technology Leadership, use of e-prescribing and
advanced decision-support capabilities could help prevent 130,000 medication errors
annually.” NAT’L GOVERNORS ASS’N, supra note 10, at 4.
20. David W. Bates et al., The Impact of Computerized Physician Order Entry on
Medication Error Prevention, 6 JAMA 313, 319 (1999). Clinical decision support systems in
e-prescribing software can perform checks against the patient’s current medications for drug
interactions, drug-allergy interactions, diagnoses, body weight, age, and correct dosing.
EHEALTH INITIATIVE, supra note 10, at 3
21. EHEALTH INITIATIVE, supra note 10, at 3. It alerts prescribers to contraindications,
adverse reactions, and duplicate therapy by using drug reference information, such as the
Physician’s Desk Reference (PDR) or Wolters Kluwer Health, Facts and Comparison. Id.; Facts
& Comparisons: About Us, WOLTERS KLUWER HEALTH, http://www.factsandcomparisons.com/a
bout-us.aspx (last visited Nov. 8, 2011).
22. Dereck L. Hunt et al., Effects of Computer-Based Clinical Decision Support Systems on
Physician Performance and Patient Outcomes: A Systematic Review, 280 JAMA 1339, 1344
(1998); see also Amit X. Garg et al., Effects of Computerized Clinical Decision Support
Systems on Practitioner Performance and Patient Outcomes: A Systematic Review, 293 JAMA
1223, 1223 (2005).
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E-prescribing also curbs illegible doctor’s scrawl,23 and misinterpreted oral
orders for medication.24 Additionally, e-prescribing reduces time spent on
the phone with pharmacies, insurers, and other health care providers and it
streamlines the medication delivery process.25 E-prescribing has been
shown to increase medication adherence and improve formulary
management for patients.26 If these benefits are not enough evidence, the
e-prescribing adoption rate speaks for itself. Between 2008 and 2009 eprescribing levels grew 284%.27 All of these benefits culminated in the
Institute of Medicine’s (“IOM”) recommendation that by 2010 “all
prescribers should write, and all pharmacies should be able to receive,
electronic prescriptions.”28
Another major benefit to e-prescribing is the significant “buy-in” from
the federal government. Beyond the new DEA rule, there have been several
initiatives to foster e-prescribing adoption. The Medicare Modernization Act
(“MMA”) established the Medicare Part D drug benefit through privatized
insurance companies.29 With the Bush Administration’s urging, one
23. EHEALTH INITIATIVE, supra note 10, at 3; The Institute of Medicine (IOM) estimates
doctor’s illegible handwriting kills thousands of people each year. Jeremy Caplan, Cause of
Death: Sloppy Doctors, TIME (Jan. 15, 2007), http://www.time.com/time/health/article/
0,8599,1578074,00.html.
24. Many oral prescription orders over the phone can be misinterpreted from the doctor
or doctor’s agent to the pharmacist or pharmacist technician. EHEALTH INITIATIVE, supra note
10, at 3.
25. Id.; CAL. HEALTH CARE FOUND., supra note 11, at 5; “Physicians and pharmacists
spend up to 25% of their time clarifying prescription orders and processing renewal requests.”
NAT’L GOVERNORS ASS’N, supra note 10, at 4. The lost wages, time and productivity from
these clarification duties may be limited by reducing potential communication failures. Id.
26. “It is estimated that 20% of paper-based prescription orders go unfilled by the
patient—at least in part due to the hassle of dropping off a paper prescription and waiting for
it to be filled.” EHEALTH INITIATIVE, supra note 10, at 4. “By eliminating or reducing this wait,
e-prescribing may help reduce the number of unfilled prescriptions.” Id. Additionally eprescribing allows health providers to track and analyze medication usage and efficacy. NAT’L
GOVERNORS ASS’N, supra note 10, at 4. Beyond the medical community, private payors and
self-insured employers recognize the benefits of e-prescribing and interoperable health
records. Larry S. Boress, An Extreme Makeover for the Employer’s House of Health Benefits,
32 J. LEGAL MED. 51, 59 (2011).
27. SURESCRIPTS, ADVANCING HEALTHCARE IN AMERICA: 2009 NATIONAL PROGRESS REPORT
ON E-PRESCRIBING, PLUS WHAT’S AHEAD IN 2010 AND BEYOND 6 (2010).
28. Robert Steinbrook, The (Slowly) Vanishing Prescription Pad, 359 NEW ENG. J. MED.
115, 116 (2008); see also INST. OF MED., PREVENTING MEDICATION ERRORS: QUALITY CHASM
SERIES 16 (2006).
29. This legislation provides seniors and individuals with disabilities with a prescription
drug benefit, more choices with privatized insurers, and better benefits under Federal
Medicare coverage. See Medicare Prescription Drug Improvement and Modernization Act of
2003, Pub. L. No. 108-173, § 101, 117 Stat. 2066, 2072 (codified as amended at 42
U.S.C. § 1395w-101(a)(1)(B)(iii)).
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provision of MMA required all insurance plans participating in the new
prescription benefit must support e-prescribing.30 Although MMA did not
mandate prescribers or pharmacies to accept electronic prescriptions,31 this
insurance plan requirement was a step toward universal adoption of eprescribing and EHR utilization. In 2008, Congress authorized the Center
for Medicare and Medicaid Services (“CMS”) to implement a Physician
Incentive Program32 under the federal statute, Medicine Improvements for
Patients and Providers Act (“MIPPA”).33 The Physician Incentive Program34
established by CMS offers financial incentives to providers who implement
electronic health records with e-prescribing capabilities.35 One of the
requirements under the program is that prescribers must “meaningfully use”
e-prescribing with a “certified” electronic health record system.36 E30. See id. § 101, 117 Stat. at 2087 (codified as amended at 42 U.S.C. § 1395w103(e)(2)(A)); see generally 42 U.S.C. §§ 1395w-101 to -154 (2006).
31. Lisette Hilton, Steady Progress in E-prescribing, AHIP COVERAGE (July/Aug. 2008),
http://216.52.120.13/content/default.aspx?bc=31%7C130%7C136%7C24075%7C24080;
see U.S. DEP’T OF HEALTH & HUMAN SERVS., MEDICARE PART D E-PRESCRIBING STANDARDS: EARLY
ASSESSMENT SHOWS PARTIAL CONNECTIVITY 4 n.9 (2009), available at http://oig.hhs.gov/oei/re
ports/oei-05-08-00320.pdf; see also Medicare Prescription Drug Improvement and
Modernization Act § 101, 117 Stat. at 2087, 2089 (codified as amended at 42 U.S.C. §
1395w-103(e)).
32. “[M]edicare Improvements for Patients and Providers Act of 2008 (MIPPA) authorizes
a new and separate incentive program for eligible professionals who are successful electronic
prescribers . . . . This new incentive program . . . began on January 1, 2009 . . . . To
participate in the . . . eRx Incentive Program, individual eligible professionals must report on
their adoption and use of a qualified eRx system by submitting claims information . . . on their
Medicare Part B claims.” Overview: Electronic Prescribing (eRx) Incentive Program, CTRS. FOR
MEDICARE & MEDICAID SERVS., https://www.cms.gov/ERxIncentive/01_Overview.asp#TopOf
Page (last visited Nov. 5, 2011) [hereinafter eRx Incentives]. To be considered for the
incentive program and potentially qualify to earn a 2% incentive payment on each eRx claim,
prescribers must report the eRx measure in at least 50% of the cases. Id.
33. See Medicare Improvements for Patients and Providers Act (MIPPA) of 2008, Pub. L.
No. 110-275, § 132, 122 Stat. 2494, 2527 (to be codified at 42 U.S.C. 1395w-4).
34. eRx Incentives, supra note 32. But see Lindsey Getz, E-Prescribing Standards — More
Clarity Needed, FOR THE RECORD, Apr. 26, 2010, at 14, 15. (“There are still many roadblocks
in the way of more widespread adoption, perhaps the most significant being the confusion that
continues to surround the process. . . . [T]he biggest problem currently seems to be a lack of
understanding about what's expected . . . .”).
35. AM. MED. ASS’N, UNDERSTANDING THE BASICS OF MEDICARE’S ELECTRONIC PRESCRIBING
INCENTIVE PROGRAM 1, available at http://www.ama-assn.org/assets/eprescribing/download
able_resources/faq-cms-incentive-program.pdf.
36. “Basically, 75% of the prescriptions have to be ePrescribed using a certified EHR
technology to meet the meaningful use guidelines.” Percent of ePrescribing for Meaningful
Use, EMR & HIPAA (April 30, 2010), http://www.emrandhipaa.com/emr-and-hipaa/2010/04/
30/percent-of-eprescribing-for-meaningful-use; see also D. Scott Jones & Howard B. Kessler,
Can Electronic Medical Records Really Improve Quality? The Obama Administration Bets Yes,
J. HEALTH CARE COMPLIANCE, Jan.–Feb. 2010, at 39, 40.
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prescribing capabilities are explicitly highlighted and emphasized as one
E-prescribing of controlled
component of the incentive program.37
substances will likely augment the prescription values used in calculating
“meaningful use,” but this has yet to be seen at the regulatory level.38
Although this topic is beyond the scope of the DEA’s regulation, it is
important to note the DEA regulation will have significant impact on
practically defining “meaningful use” of e-prescribing for the incentive
program under MIPPA.39
The private sector has spurred the growth of e-prescribing as well.
Several private initiatives, by insurers and other payors, have increased the
frequency of e-prescribing.40 Most notably the National ePrescribing Patient
Safety Initiative (“NEPSI”) coalition is dedicated to the increased use of eprescribing software.41 NEPSI has offered free software to physicians that

37. Jones & Kessler, supra note 36, at 40.
38. This has yet to be discussed or implemented but the ONC (Office of the National
Coordinator for Health Information Technology), a branch of HHS, has the duty and plans to
implement Stage 2 of the incentive program and the new DEA regulation will likely be
addressed at that time. See OFFICE OF THE NAT’L COORDINATOR FOR HEALTH INFO. TECH., U.S.
DEP’T OF HEALTH & HUMAN SERVS., HIT POLICY COMMITTEE: MEANINGFUL USE WORKGROUP
REQUEST FOR COMMENTS REGARDING MEANINGFUL USE STAGE 2, at 1, 5 (2011), available at
http://healthit.hhs.gov/portal/server.pt/document/954501/mu_rfc__2011-01-12_final_pdf.
“[C]MS will have an eye on incorporating the Department of Justice’s policy regarding the
electronic prescribing of Schedule II drugs, perhaps as soon as the implementation of Stage
Two eRx meaningful use criteria.” Mark Faccenda & Lara Parkin, Meaningful Use—What
Does It Mean to You?, HEALTH LAW., Feb. 2011, at 10, 13. This author speculates that if the
physician must e-prescribe a certain percentage of prescriptions each quarter or annually, the
controlled substances will be included in those calculations once controlled substances are
able to be e-prescribed. See id. Additionally, it could be speculated that controlled
substances would not be used in the calculation if a given state were not allowing providers to
e-prescribe controlled substances.
39. Electronic Prescriptions for Controlled Substances, DRUG ENFORCEMENT ADMIN. (Mar.
31,2010), http://www.deadiversion.usdoj.gov/ecomm/e_rx/faq/eapplications.htm [hereinafter
DEA eRx].
40. A small list of private initiatives include: Massachusetts eRx Collaborative,
Southeastern Michigan e-Prescribing Initiative, National ePrescribing Patient Safety Initiative,
BlueCross Blue Shield E-Prescribing Programs, and Individual State Initiatives. CTR. FOR
HEALTH TRANSFORMATION, ELECTRONIC PRESCRIBING: BUILDING, DEPLOYING, AND USING EPRESCRIBING TO SAVE LIVES AND SAVE MONEY 16-24 (2008), available at http://www.sures
cripts.com/media/660347/cht_eprescribing_paper_06.10.2008.pdf.
41. “This coalition-based program is comprised of healthcare, technology and provider
companies dedicated to positively impacting the national prescribing process through
electronic prescribing (ePrescribing) delivery. NEPSI delivers on this commitment by offering
free ePrescribing to every physician and medication prescriber in America.” About Us, NAT’L
EPRESCRIBING PATIENT SAFETY INITIATIVE (2008), http://www.nationalerx.com/about-us.htm.
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encounter financial barriers in their practice.42 The private initiatives noted
are merely a small sample of programs started to encourage the growth of
e-prescribing.43 Beyond the MMA,44 Physician Incentive Program,45 and
private or state initiatives,46 the new DEA regulation will have significant
impact in removing the “controlled substance barrier” or excuse stopping
prescribers from implementation.47 The DEA rule closes a major loophole
in e-prescribing language by authorizing e-prescribing for all medications.
There are barriers to implementation of e-prescribing for providers,
pharmacies, and patients. There is a substantial financial cost to providers,
pharmacies, and insurers to set-up the necessary hardware and software,
not to mention the requisite training for staff, to ensure a successful eprescribing program is in place.48 In particular, independent physician
offices and small health systems may not immediately realize the return on
investment (“ROI”) from e-prescribing.49 With high initial set-up costs and a
low pay-out, for efficiency and streamlined communication, cash-strapped
physician offices have had little incentive to implement an e-prescribing
system.50 However, large health systems that have implemented an all
encompassing EHR system have found it much easier to integrate an eprescribing component.51

42. “NEPSI aims to eliminate the burdens and barriers to ePrescribing adoption that can
be experienced by providers.” Prescribers, NAT’L EPRESCRIBING PATIENT SAFETY INITIATIVE
(2008), http://www.nationalerx.com/prescribers.htm.
Allscripts, a leading e-prescribing
intermediary that hosts the e-prescribing service, offers software, internet hosting, training, and
support to all eligible prescribers. Id. Ultimately the NEPSI project helps implement, promote,
and utilize e-prescribing practices for poor, small, and sometimes rural physician offices. See
id.
43. CTR. FOR HEALTH TRANSFORMATION, supra note 40, at 16.
44. See Medicare Prescription Drug, Improvement, and Modernization Act of 2003,
Pub. L. No. 108-173, 117 Stat. 2066 (codified as amended in scattered sections of 42
U.S.C.).
45. See Medicare Improvements for Patients and Providers Act (MIPPA) of 2008, Pub. L.
No. 110-275, § 132, 122 Stat. 2494, 2527 (to be codified at 42 U.S.C. 1395w-4); eRx
Incentives, supra note 32.
46. CTR. FOR HEALTH TRANSFORMATION, supra note 40, at 16-24.
47. See Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. 16,236
(proposed Mar. 31, 2010) (to be codified 21 C.F.R. at pts. 1300, 1304, 1306, 1311).
48. EHEALTH INITIATIVE, supra note 10, at 4-5; Steinbrook, supra note 28, at 115; CAL.
HEALTHCARE FOUND., supra note 11, at 37.
49. EHEALTH INITIATIVE, supra note 10, at 4, 6. Stand-alone e-prescribing systems cost
approximately $3,000 per physician; fully integrated systems can cost $50,000 per physician.
NAT’L GOVERNORS ASS’N, supra note 10, at 2; see also Sullivan, supra note 6, at 19.
50. EHEALTH INITIATIVE, supra note 10, at 4.
51. See Ashish K. Jha et al., A Progress Report On Electronic Health Records in U.S.
Hospitals, 29 HEALTH AFF. 1951, 1956 (2010); CAL. HEALTHCARE FOUND., supra note 11, at
38; NAT’L GOVERNORS ASS’N, supra note 10, at 2.
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There will always be inherent flaws in any e-prescribing system such as
typos, computer crashes, entry mistakes, unauthorized record retrieval, and
other errors.52 The data retrieved from a working e-prescribing system is
only as good as the data that is originally entered.53 Another obstacle that
has providers and health systems dragging their feet toward e-prescribing
adoption is the inherent distrust of computer software.54 Computer software
cannot take into account every patient’s condition and prognosis; what may
be a dangerous contraindication for one patient may be a life-saving
therapy for another.55 The fail-safe warnings and alerts can seem
cumbersome and dangerous in certain areas of medical practice.56 It is
also important to note a cultural barrier associated with e-prescribing, for
many physicians and pharmacists the way prescriptions are delivered has
not changed since the advent of facsimile.57 This new technology is
interfering with the usual workflow of health care providers.58
Until recently controlled substances, 10% to 11% of all prescriptions,
were not eligible for e-prescribing and this may have been a significant
barrier for practices that focused on prescribing narcotics (i.e. pain clinics,
headache clinics, and surgical care centers that discharged patients with
pain medication).59 A final barrier that should be noted one states’ varying

52. Ross Koppel et al., Role of Computerized Physician Order Entry Systems in Facilitating
Medication Errors, 293 JAMA 1197, 1198-1200 (2005).
53. See id. at 1200-01.
54. Scot Silverstein, Barriers to Computerized Prescribing, 280 JAMA 516, 516 (1998).
“The United States ranks in the bottom half (out of 11 countries) on every metric used to
measure adoption, including use of electronic medical records (10th), electronic prescribing
(10th), electronic clinical note entry (10th), electronic ordering of laboratory tests (8th), electronic
alerts/prompts about potential drug dose/interaction problems (8th) and electronic access to
patient test results (7th).” Thomas R. Nathan, Federal Communications Commission, National
Broadband Plan, Health Care, in 1 BROADBAND & CABLE INDUSTRY LAW 161, 168 (2011).
55. See Gordon D. Schiff & David W. Bates, Can Electronic Clinical Documentation Help
Prevent Diagnostic Errors?, 362 NEW ENG. J. MED. 1066, 1067-68 (2010).
56. Tyler Chin, Doctors Pull Plug on Paperless System, AM. MED. NEWS (Feb. 17, 2003),
http://www.ama-assn.org/amednews/2003/02/17/bil20217.htm; see Thomas Bodenheimer
& Kevin Grumbach, Electronic Technology: A Spark to Revitalize Primary Care?, 290 JAMA
259, 261-63 (2003).
57. Silverstein, supra note 54, at 516; Chin, supra note 56; see Bodenheimer &
Grumbach, supra note 56, at 260.
58. EHEALTH INITIATIVE, supra note 10, at 5. But see Gerard P. Filicko, Don’t Drop the
Baton: e-Prescribing and e-Results Improve Workflow, VITALSTATISTICS, Summer 2006, at 24,
24, available at http://www.medvirginia.net/includes/20060705_VS_eRx.pdf.
59. Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. 16,236, 16,237
(proposed Mar. 31, 2010) (to be codified 21 C.F.R. at pts. 1300, 1304, 1306, 1311); see
Douglas Blayney, ePrescribing and Scheduled Narcotics for Pain Control in Cancer Patients,
ASCO CONNECTION (Jan. 23, 2009, 1:40 AM), http://connection.asco.org/commentary/arti
cle/id/2648/eprescribing-and-scheduled-narcotics-for-pain-control-in-cancer-patients.aspx.
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rules and legislative language.60 This legislative or regulatory disarray could
cause a significant slow-down in the adoption of e-prescribing of controlled
substances.
II. THE NEW DEA RULE SYNOPSIS
The new DEA rule promulgated in March 2010 has significant impact in
the area of e-prescribing. First, the DEA authorized the electronic
prescribing of controlled substances.61 This essential step closes the disjoint
between incentivizing the use of e-prescribing but not encompassing 1011% of all drugs prescribed nationally, controlled substances.62 By allowing
controlled substances to be prescribed electronically, physicians and
pharmacists have one less barrier (or excuse) to hinder their implementation
of e-prescribing.63
Second, the regulation enumerates who may e-prescribe controlled
substances.64 It cannot be an agent (e.g. nurse, receptionist) but must be
the prescriber.65 Prescribers are eligible if they possess a valid DEA license,
which may be linked to the e-prescribing information to assist with a
Third, the DEA regulation has implemented
seamless transition.66
recordkeeping requirements for e-prescribing of controlled substances.67
The records must be readily retrievable and must be kept for up to two
years, which is consistent with the current recordkeeping standards for paper
prescriptions of controlled substances.68 Additionally, e-prescribing software
must allow prescribers the ability to review monthly logs of all controlled

60. EHEALTH INITIATIVE, supra note 10, at 5.
61. Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. at 16,307.
62. Id. at 16,237.
63. See Kate Ackerman, Long-Awaited DEA Rule on Controlled Substances Could Boost ERx Rates, IHEALTHBEAT (April 8, 2010), http://www.ihealthbeat.org/features/2010/longawait
ed-dea-rule-on-controlled-substances-could-boost-erx-adoption.aspx#.
64. Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. at 16,311-12.
65. Id. at 16,311. DEA guidance has confirmed and clarified that DEA registrants should
not delegate prescribing to an agent because a non-prescribing agent is not able to make a
clinical decision in the place of a prescriber. See also 21 C.F.R. § 1306 (2010). Agents’
duties are limited to ministerial acts in connection with communicating prescription
information to a pharmacy. Role of Authorized Agents in Communicating Controlled
Substance Prescriptions to Pharmacies, 75 Fed. Reg. 61,613, 61,614 (Oct. 6, 2010) (to be
codified at 21 C.F.R. pt. 1306).
66. Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. at 16,245, 16,307,
16,312.
67. Id. at 16,306-07.
68. Id. at 16,307. This was an issue of contention. The first rule had a 5-year window
for record retrieval but after significant “push-back” from medical and pharmacy practitioners,
the DEA revised this to a 2-year window as is consistent with current paper recordkeeping
standards. Id. at 16,261.
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medications.69 Prescribers are not required to sign off on monthly reports,
but must have the software capabilities to retrieve the reports.70
Finally, and most importantly, the DEA established a “two factor
authentication” requirement.71 The requirement mandates that prescribers
use two out of three types of authentication to verify their identity before
transmitting an e-prescription for a controlled substance.72 The three types
of authentication have been hotly contested, as seen in the comments of the
DEA Rule.73 The rule requires two of the three methods of authentication:
(1) a hard token or key type device that the prescriber must have on them;74
(2) a password or knowledge-based security measure;75 or (3) a biometric
security measure.76 Succinctly put, something the prescriber knows, has in

69. Id. at 16,263
70. Initially, the rule called for prescribers to review and sign a monthly log and keep the
log in a separate record for DEA review. After the initial comment period, this rule was
reduced to simply printing and retrieving such logs. Physicians successfully argued that with
the implementation of e-prescribing and more paperwork this monthly log redundancy would
severely inhibit workflow. Id. at 16,262-63.
71. Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. at 16,312.
Commentators voiced initial concern that a two-factor method would be too burdensome;
however, the DEA insisted on a two-factor security measure citing specific internal security
issues. Id. at 16,249. “The problem DEA is addressing with the requirement for two-factor
authentication credentials is not that someone may use their own authentication credential to
alter or create a prescription, but that a nonregistrant will use a registrant’s authentication
credential to create and sign a prescription.” Id. The risk for a single authentication/password
to be duplicated or given out is too great a risk to the internal security of a physician’s office.
Id.
72. Id. at 16,312.
73. Id. at 16,249.
74. The hard token itself must be separate from the computer and physically in possession
of the prescriber. Id. at 16,312. During the rules comment period, commenters suggested a
swipe card, key-like device, or any other physical object, which would identify and give access
to the physician. Id. at 16,253. For example, if a physician had a password and token the
computer entry would be similar to an ATM interaction. Id. at 16,243.
75. The DEA recognized and addressed password security standards in reference to
length, complexity, and prescriber’s ability to remember the password. Electronic Prescriptions
for Controlled Substances, 75 Fed. Reg. at 16,312 (citing KAREN SCARFONE & MURUGIAH
SOUPPAYA, NAT’L INST. OF STANDARDS & TECH., NIST SPECIAL PUB. 800-118, GUIDE TO
ENTERPRISE PASSWORD MANAGEMENT (DRAFT) ES1 (2009), available at http://csrc.nist.gov/publi
cations/drafts/800-118/draft-sp800-118.pdf). Software companies are expected to produce
password authentication measures based on these generally accepted password standards. Id.
at 16,249.
76. The DEA found that 18% of prescribers use (and 36% plan to use) biometric markers
for log-in to EHR systems which compelled the DEA to include, but not mandate, use of
biometrics. Id. at 16,250. Biometric passcodes could include fingerprint scans, retina scans,
etc . . . which must operate at a generally acceptable accuracy and “false match rating.” Id.
at 16,312.
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his or her possession, or the prescribers himself or herself.77 In addition to
these authentication measures, the DEA has recognized that an actual
electronically scanned signature could accompany the prescriptions.78
There have been other specific concerns brought to light within the
comments but many of those addressed were grouped together and
summarized by the DEA’s response.79 Arguably many of these concerns are
minor in nature and can be solved through DEA guidance in the future. It is
reasonable to assume the DEA cannot solve unascertained problems given
that e-prescribing technology is constantly evolving.
III. THE STATE AND FEDERAL INTERPLAY
With the implementation of these new rules it could be argued that
finally, after years, e-prescribing is reaching full integration into the health
care delivery model.80 Prior to the new rule, prescribers and pharmacies
were not allowed to write for or dispense prescriptions for controlled
substances (CI-CV) via electronic means.81
Controlled substance
prescriptions make up 10 – 11% of all prescribed medications and until now
were a missing link in the chain of medication delivery.82 Controlled
substances are habit-forming medications that are rated on their medical
necessity and potential for abuse.83 From drugs that are labeled CI (e.g.
77. Id. at 16,312.
78. The DEA wants to grant prescribers the flexibility and the authority to customize their
prescriptions. Id. at 16,260. The DEA further notes that the use of a physical signature is
optional but the “two-factor” authentication is mandatory. Id. The reliance on a single
password system is not secure enough and is often considered the weakest link in technology
security. Id. at 240.
79. Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. at 16,244. The DEA
gave consideration to over 200 different comments while drafting the interim final rule that is
now being implemented. DEA eRx, supra note 39; see also Ken Tubman, ePrescribe
Controlled Substances in 2010?, E-PRESCRIBING BLOG (Mar. 30, 2010), http://www.epre
scribing.org.
80. Overview: E-Prescribing, CTRS. FOR MEDICARE & MEDICAID SERVS., https://www.cms.
gov/eprescribing/ (last visited Jan. 2, 2012).
81. M. Susan Ridgley & Michael D. Greenberg, Pharmacy, Facsimile, and Cyberspace:
An Examination of Legal Frameworks for Electronic Prescribing, 13 ALB. L.J. SCI. & TECH. 1, 33
(2002).
82. Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. at 16,237; Lawrence
Bell, Health Care Primer: E-Scripts, Physician-Pharmacists Safe Harbors, Additional Physician
Revenue, J. COMPENSATION & BENEFITS, May/June 2008, at 14, 24 (2008); see also
Ackerman, supra note 63.
83. DRUG ENFORCEMENT ADMIN., U.S. DEP’T OF JUSTICE, PRACTITIONER’S MANUAL: AN
INFORMATIONAL OUTLINE OF THE CONTROLLED SUBSTANCES ACT 5, 6 (2006) [hereinafter
PRACTITIONER’S MANUAL], available at http://www.deadiversion.usdoj.gov/pubs/manuals/
pract/pract_manual012508.pdf; see generally 21 C.F.R. §§ 1308.11-.15 (2010)
(categorizing specific substances and chemical compounds).
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heroin) to drugs labeled CV (e.g. codeine cough syrup) the Secretary of
Health and Human Services (“HHS”) categorizes and enforces federal
regulations on all habit-forming medications.84 The authority to do so was
granted by Congress in the Controlled Substance Act (“CSA”)85 and
subsequent DEA regulations.86 The DEA however, does not have the
authority to preempt state laws or mandate states enforce e-prescribing of
controlled substances at the state level.87 While the constitutionality of the
DEA regulations is beyond the scope of this article, the interplay between
state and federal regulations of controlled substances must be addressed to
truly understand how this regulation may be implemented.88
Although the CSA grants the federal government authority over all
controlled substance, from manufacturing to dispensing, HHS and DEA
work in close collaboration with state regulatory agencies (e.g. state boards
of medicine, pharmacy, nursing).89 States retain the ability to legislate and
regulate more stringently beyond the DEA and other federal regulations
concerning controlled substances.90 Traditionally, the federal role in
prescription drug management has been three-fold: (1) the DEA has the
authority to register providers and dispensers of controlled substances; (2)
the DEA has the ability to classify narcotic medications; and (3) the DEA
enforces all federal drug policy.91 The DEA registers92 and regulates
pharmacies.93 Every pharmacy that dispenses controlled substances has a

84. The Secretary of HHS has the actual authority to schedule all controlled drugs but
does so at the professional expert opinions of both the FDA and DEA. 21 C.F.R. § 1308.43
(2010).
85. See generally 21 U.S.C. §§ 801-890 (2006).
86. See generally 21 C.F.R. §§ 1300-1316 (2010) (granting DEA approval and
regulatory authority over controlled substance activities).
87. Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. at 16,304.
88. Lars Noah, Ambivalent Commitments to Federalism in Controlling the Practice of
Medicine, 53 U. KAN. L. REV. 149, 177 (2004).
89. “The DEA registration grants practitioners federal authority to handle controlled
substances. However, the DEA registered practitioner may only engage in those activities that
are authorized under state law for the jurisdiction in which the practice is located.”
Practitioner’s Manual, supra note 83, at 7.
90. Id.
91. See generally id. at 5-13 (describing the DEA’s procedures for registration,
classification, and reporting).
92. The DEA requires each individual prescriber to register if they wish to write
prescriptions for controlled substances. Id. at 7. Individual pharmacists do not need to
register, but rather the pharmacy entity itself must register with the DEA if they wish to dispense
controlled drugs. Id. at 8.
93. “[Pharmacist/Pharmacy] must issue an official order form (DEA Form 222) or an
electronic equivalent to the registrant transferring the drugs.” DRUG ENFORCEMENT ADMIN.,
U.S. DEP’T OF JUSTICE, PHARMACIST’S MANUAL: AN INFORMATIONAL OUTLINE OF THE CONTROLLED
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DEA registration number and must execute special “222 Order Forms” to
procure prescription medication from a drug wholesaler or manufacturer.94
Coupled with the DEA influence over controlled substances, individual
states have significant power to influence controlled substance regulations.95
States may create controlled substance regulations that are more stringent
than the CSA96 or DEA regulations97 either through classification of
medications, recordkeeping requirements, or even where controlled
medication may be stored.98 An example of a state legislating beyond the
DEA is in Illinois. Illinois classified the drug Talwin® (pentazocine) as a CII
narcotic99 whereas the DEA classified the drug as a CIV a narcotic.100 States
always reserve the right to implement stricter regulations than those

SUBSTANCES ACT 10 (2010) [hereinafter PHARMACIST’S MANUAL], available at
http://www.deadiversion.usdoj.gov/pubs/manuals/pharm2/pharm_manual.pdf.
94. There are a number of forms that pharmacies must execute to be eligible for the
purchase, transfer, and dispensing of controlled drugs (e.g. 222 Form, 41 Form, 224 Form,
etc.). Id. at 13; DRUG ENFORCEMENT ADMIN., FORM DEA-224 APPLICATION FOR REGISTRATION,
available at http://depts.washington.edu/uwmedres/professional/faq_files/224_form_09
05.pdf (last visited Jan. 2, 2012); SAMPLE DEA FORM 222, available at http://www.zoo
pharm.net/images/pdf/dea222-sample.pdf (last visited Jan 2, 2012).
95. For example, West Virginia and Arizona have in place a more stringent controlled
substance monitoring program in addition to a separate registration of all prescribers. See W.
VA. CODE ANN. § 60A-9-3 (LexisNexis 2011); ARIZ. REV. STAT. § 36-2608 (LexisNexis 2011).
Iowa has had a separate registration process in effect for a number of years. See IOWA BD.
OF PHARMACY, NEW IOWA CONTROLLED SUBSTANCES ACT REGISTRATION APPLICATION (2011),
available at http://www.iowa.gov/ibpe/pdf/csa-new.pdf. Delaware has set-up a separate
group, Delaware Office of Controlled Substances, to deal with all controlled substance
monitoring and prescribing within the state. DEL. CODE ANN. tit. 16, §§ 4701-4796 (2011).
96. See 21 U.S.C. §§ 801-890 (2006).
97. The examples in note 95 go above and beyond the call of the DEA regulations and
the normal standards set forth by the federal agency. See generally 21 C.F.R. §§ 1300-1316
(2010).
98. See 720 ILL. COMP. STAT. 570 / 312(a) (2010). Wisconsin requires that all CII
narcotic medication be either stored in a safe or stored in a manner that is not easily
accessible. WIS. ADMIN. CODE PHAR. § 6.07 (2010).
99. 720 ILL. COMP. STAT. 570 / 312(a) (2010). The Illinois Department of Financial and
Professional Regulations, an overarching department including the Illinois Board of Pharmacy,
has found Talwin® (pentazocine/naloxone) to be a drug of particular abuse in certain regions
of Illinois and has thus scheduled it separately from the DEA regulations. May Annexton,
Pentazocine Reclassified in Illinois, 240 JAMA 2234, 2235 (1978). The Illinois Board of
Pharmacy requires special “222-like” order forms be completed and sent to the Board in
order for any pharmacy to purchase and dispense Talwin®. Id.
100. DRUG ENFORCEMENT ADMIN., U.S. DEP’T OF JUSTICE, CONTROLLED SUBSTANCES—BY
DEA DRUG NUMBER 10 (2011), available at http://www.deadiversion.usdoj.gov/schedules/or
angebook/d_cs_drugcode.pdf.
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established by the DEA.101 Another example of states legislating around the
CSA is a more stringent record-keeping requirement. Some states
(Nebraska102 and Oregon103) require that pharmacies maintain controlled
substance records for several years after dispensing the medication. The
DEA regulation only requires records to be maintained for two years.104
It is possible to have a disconnect between the goals and standards of
the DEA and the execution, implementation, and enforcement of regulations
at the state level. A competing interest might influence how this new DEA
regulation may be enforced. Ultimately, the practical implications of eprescribing controlled substances rests within the states’ control, and the
DEA’s regulations are simply a baseline for the states to implement.105
With this new rule, health care providers will be able to write for and
dispense all prescriptions electronically, if they so choose.106 Health care
providers, pharmacies, and government entities are reexamining barriers to
e-prescribing, as evidenced by the comments to the DEA rule.107 Some of
these traditional barriers to e-prescribing will still be at issue, such as
financial barriers,108 cultural barriers,109 training,110 and privacy.111
However, additional barriers at the state level may be of increasing concern,

101. Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. 16,236, 16,304
(proposed Mar. 31, 2010) (to be codified 21 C.F.R. at pts. 1300, 1304, 1306, 1311);
PRACTITIONER’S MANUAL, supra note 83, at 7.
102. Controlled substance records must be retained for five years. NEB. REV. STAT. § 28411 (2008).
103. Records of all prescriptions must be kept for three years. OR. REV. STAT. § 689.508
(2009).
104. PHARMACIST’S MANUAL, supra note 93, at 13. However, many states only require a
two-year record keeping standard as well. See, e.g., 04-02-0010 ARK. CODE R. § 70
(LexisNexis 2010); MINN. STAT. ANN. § 151.211 (West 2011); IOWA ADMIN. CODE r. 657-21-5
(2009).
105. PRACTITIONER’S MANUAL, supra note 83, at 7.
106. Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. at 16,236.
107. Id.; see also Ackerman, supra note 63.
108. EHEALTH INITIATIVE, supra note 10, at 4; Ackerman, supra note 63.
109. Silverstein, supra note 54, at 516.
110. EHEALTH INITIATIVE, supra note 10, at 4.
111. Michael D. Greenberg et al., Electronic Prescribing and HIAPA Privacy Regulation, 41
INQUIRY 461, 466 (2004); Angela Ferneding, Regional Health Information Organizations:
Lower Health Care Costs, Fewer Iatrogenic Illnesses, and Improved Care—What Are We
Waiting For?, 22 J. L. & HEALTH 167, 181-82 (2009); Sullivan, supra note 6, at 18.
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such as regulatory inconsistencies at the state level,112 drug diversion, or
data security.113
IV. FOCUSING IN ON STATE REGULATORY BARRIERS: UNADDRESSED ISSUES
This may leave the DEA and e-prescribing stakeholders in a precarious
position. The DEA has promulgated a rule that took years to come to
fruition.114 At least two presidential administrations115 and Congressional
sessions116 have backed e-prescribing; and now the rule is ready to be
implemented. States may still legislate around the DEA rule by passing
more stringent laws and regulations.117 This paper will address the varying
legislative structure of states’ e-prescribing laws and the motivating factors
behind their decisions to legislate or to stay silent on this new medication
delivery process that the federal government has so heavily invested in.118
States may for many reasons see e-prescribing as a potential risk. States
may be resistant to e-prescribing because of privacy issues,119 forgery or
diversion risks,120 increase in costs to small or rural prescribers,121 or simply

112. Most states have not addressed e-prescribing and STARK and anti-kickback
implications. Ferneding, supra note 111, at 178-180; Sullivan, supra note 6, at 19. See
generally Bell, supra note 82, at 22-24.
113. Gilman & Cooper, supra note 5, at 282-83; Ferneding, supra note 111, at 183-84;
Sullivan, supra note 6, at 17-18.
114. The first attempt at e-prescribing of controlled substances was on April 1, 2005. Lisa
M. Power, DEA Final Rule Sets The Course For E-Prescribing of Narcotics, HEALTH LAW., Aug.
2005, at 32, 32; Overview: E-Prescribing, supra note 80.
115. Jones & Kessler, supra note 36, at 41; Seth H. Lundy et al., Just What the Doctor
Ordered? CMS and DEA Introduce New Measures to Facilitate E-Prescribing, J. HEALTH & LIFE
SCI., July 2009, at 79, 85.
116. Lundy et al., supra note 115, at 85.
117. Precedent of disregard for the DEA’s regulations is prominently illustrated by
California’s regulation and validation of marijuana prescriptions. CAL. HEALTH & SAFETY CODE
§ 11362.5 (West 2011). Other states have created legislation to legislate around less
controversial DEA regulations. See, e.g., NEB. REV. STAT. § 28-411 (2008), 720 ILL. COMP.
STAT. 570 / 312(a) (Supp. 2009).
118. In 2010 alone, CMS budgeted and spent over $24 million dollars for e-prescribing
and requested $27.7 million in 2011. CTRS. FOR MEDICARE & MEDICAID SERVS., U.S. DEP’T OF
HEALTH & HUMAN SERVS., FISCAL YEAR 2011: JUSTIFICATION AND ESTIMATES FOR APPROPRIATIONS
COMMITTEES 3, 66 (2011), available at http://www.cms.gov/PerformanceBudget/Downloads/
CMSFY11CJ.pdf.
119. Greenberg et al., supra note 111, at 466; Ferneding, supra note 111, at 183;
Sullivan, supra note 6, at 18.
120. Gilman & Cooper, supra note 5, at 283; Ferneding, supra note 111, at 182-83;
Sullivan, supra note 6, at 17-18.
121. EHEALTH INITIATIVE, supra note 10, at 4; Ackerman, supra note 63.
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lag behind the DEA regulation change,122 an statute and rule language
disarray.123 To further analyze states responses to the DEA rule this analysis
must delve into state language and motivations to better understand the
nature of implementation of e-prescribing.
California may be the most favorably situated state to implement eprescribing of controlled substances.124 California’s statutory and regulatory
language seems consistent with the DEA regulation and is so flexible that
there seems to be cohesion between statute,125 regulation,126 and
enforcement guidelines.127
With the approval of the CA BoP and the Department of Justice, a
pharmacy may receive electronic data transmission prescriptions or
computer entry prescriptions or orders for C II, III, IV, or V drugs if
authorized by federal law and in accordance with regulations promulgated
by DEA. The CA BoP shall maintain a list of all such requests and approvals
granted.128

Additionally, the deputy attorney general has pressed for a quick
adoption to e-prescribing of controlled substances.129 Current statutes allow
for adoption of e-prescribing of controlled substances as soon as feasibly
possible.130 The California legislature wisely adopted language that gave

122. See Narcotic Enforcement, N.Y. DEP’T OF HEALTH, http://www.health.state.ny.us/pro
fessionals/narcotic/ (last visited Jan. 2, 2012).
123. Many states have conflicting legislation and code language See W. VA. CODE ANN. §
30-5-12c(a), (c) (LexisNexis 2011).
124. Jeff Todd, E-prescribing in a Changing Legal Environment, RICH. J.L. & TECH., Spring
2006, at 1, 11-12.
125. “Electronic transmission of prescriptions is generally permitted.” CAL. BUS. & PROF.
CODE § 4040 (West 2011). For over fourteen years, California has included e-prescription as
a valid mode of prescription transfer in its laws. Joshua A. Room, Deputy Att’y Gen., Cal.
Dep’t Justice, Presentation to the California Board of Pharmacy: The Legal Landscape of
Electronic Prescribing (E-Prescribing) in California (Nov. 20, 2008), available at
http://www.pharmacy.ca.gov/meetings/agendas/legal_landscape.pdf.
126. California regulations requiring the components of a prescription are not technologyspecific and, as such, can be interpreted within e-prescribing mediums. Room, supra note
125.
127. Upon DEA approval, the Board of Pharmacy in California and the local DOJ liaisons
have the authority to “green-light” e-prescribing of controlled substances. Id.; see also CAL.
HEALTH & SAFETY CODE § 11164.5(a) (West 2011); Stephen Barlas, DEA Opens the Door to ePrescribing of Controlled Substances: But Pharmacies Balk at Security Rules, 33 P&T 626, 626
(2008).
128. HEALTH & SAFETY § 11164.5(a).
129. The deputy attorney general noted that California is “poised” for DEA approval.
Room, supra note 125.
130. See HEALTH & SAFETY § 11164.5(a).
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the Board of Pharmacy, Department of Justice, and DEA the final check on
any e-prescribing of controlled substance policies.131
California has amended its laws to skirt anti-kickback rules by creating
“safe harbors” for e-prescribing.132 This potentially will facilitate a greater
adoption of the practice. States that do not have safe harbors or carve-outs
to anti-kickback legislation may find that prescribers expose themselves to
fraud and abuse liability.133 This issue is addressed on a federal level,134
and certain states may have addressed this after the adoption of eprescribing of non-controlled substances,135 however, states that employ

131. Only with the approval of the Board of Pharmacy and the Department of Justice, and
only if authorized by federal law and DEA regulations, may a hospital or pharmacy receive eprescriptions for any controlled substance. Id. Additionally, one of the California Board of
Pharmacy’s stated objectives in their strategic plan to is analyze and implement the legal
requirements of e-prescribing of controlled substances at the earliest date. CAL. STATE BD.
PHARMACY, STRATEGIC PLAN 2006-2011, at 12 (2009), available at http://www.pharma
cy.ca.gov/publications/strategicplan_2009.pdf.
132. CAL. WELF. & INST. CODE § 14107.2(c)(4) (West 2011); CMS Proposes New
Exemptions for 2012 E-Prescribing Penalty, CAL. MED. ASS’N. (May 31, 2011), http://www.cm
anet.org/news/detail?article=cms-adds-new-exemptions-for-2012-e-prescribing.
133. See Kathy Poppit et al., New E-Prescribing and EHR Exceptions and Safe Harbors,
HEALTH LAW. NEWS, Nov. 2006, at 24, 25-26, available at http://www.healthlawyers.org/Mem
bers/PracticeGroups/LS/Documents/Poppitt.pdf; see also Federal Fraud and Abuse: AntiKickback Statute, TELEHEALTH RESOURCE CENTER, http://www.telehealthresourcecenter.org/tool
box-module/federal-fraud-and-abuse-anti-kickback-statute (last visited Jan. 2, 2012)
(explaining that states can have anti-kickback statutes varying from the federal one, but that
specific exceptions for electronic prescribing can exist). Many states have anti-kickback
statutes, including California, Florida, Georgia, Massachusetts, New Jersey, North Carolina,
and Texas. Anti-Kickback Law and Suspect Financial Agreements: FAQ, AM. C. OF RADIOLOGY
(Apr. 1999), http://www.acr.org/secondarymainmenucategories/businesspracticeissues/fea
turedcategories/antikickback/antikickbacklawandsuspectfinancialagreementsfaqdoc3.aspx.
134. The e-prescribing STARK law exception was required by the Medicare Prescription
Drug Improvement and Modernization Act of 2003, and states that the agency's authority to
issue the electronic medical record exception is justified under the agency’s “legal authority
under section 1877(b)(4) of the [Social Security Act].” Medicare Program; Physicians Referrals
to Health Care Entities With Which They Have Financial Relationships; Exceptions for Certain
Electronic Prescribing and Electronic Health Records Arrangements, 71 Fed. Reg. 45,140,
45,140 (Aug. 8, 2006) (to be codified at 42 C.F.R. pt. 411). This exception was effective in
October 2006 and expires in 2013. Ferneding, supra note 111, at 179; see 42 C.F.R.
§1001.952 (2010). This 2006 rule by CMS preempts states from disallowing e-prescribing
for any federally funded plans and carves out e-prescribing from the anti-kickback statute. Id.
However, non-federally funded individuals are still regulated by the laws of the state via
private insurance companies; Medicaid is not mandated by incentive programs to e-prescribe
yet either. Id.; see also NAT’L CONFERENCE OF STATE LEGISLATURES, ELECTRONIC PRESCRIBING 45 (2009), available at http://www.ncsl.org/documents/health/eprscrb0209.pdf (noting that
although Medicaid does not fall under the Medicare e-prescribing program, efforts exist in
states to establish similar programs).
135. EHEALTH INITIATIVE, supra note 10, at 7.
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anti-kickback legislation may need to accommodate for a new surge in
adoption of e-prescribing.136
In 2008, California Governor Arnold Schwarzenegger proposed
legislation to mandate e-prescribing capabilities for all California
Another great driver of California’s
prescribers and pharmacies.137
favorable e-prescribing environment is the California HealthCare
Foundation (“CHCF”) which has championed the cause through pilot
projects, market assessments, and facilitation of discussions.138 California’s
incentive programs are numerous at the public and private level. Private
insurance payors are incentivizing e-prescribing beyond the scope of the
federal initiatives.139 California’s flexible, all-encompassing statute and rule
language will allow for what appears to be a seamless adoption of the DEA
regulations. Some states are not far behind California’s example. Arizona
is similarly situated with legislation that reads:
For electronic transmission of a Schedule II, III, IV, or V controlled substance
prescription order, the medical practitioner and pharmacy shall ensure that
the transmission complies with any security or other requirements of federal
law.140

This law seems to be in compliance with the new DEA regulation making
Arizona ready to implement e-prescribing of controlled substances. Utah is
another forward thinking state with its passage of the Electronic Prescribing
Act.141 Utah requires, a prescriber to ask the patient if they would like to opt
into an e-prescribing program.142 The law also requires all pharmacies be

136. See NATIONAL CONFERENCE OF STATE LEGISLATURES, supra note 134 at 4-5.
137. Governor Schwarzenegger’s health plan, under Senate Bill ABX1 1, would have
mandated all pharmacies, prescribers, and insurance plans be able to e-prescribe by January
1, 2012. CAL. STATE S., S. HEALTH COMM. ANALYSIS, HEALTH INSURANCE REFORM, ABX1 1, 1st
Extraordinary Sess., at 40 (2008), available at http://senweb03.senate.ca.gov/committee/stan
ding/health/ABX1.pdf.
138. Fostering Adopting of E-Prescribing in California, CAL. HEALTHCARE FOUND. (Nov.
2008), http://www.chcf.org/projects/2008/fostering-adoption-of-eprescribing-in-california.
139. The state Medicaid program, Medi-Cal, has worked with local providers, pharmacists,
and private insurance entities to facilitate comprehensive pilot programs to iron out any
wrinkles to the e-prescribing system. SUSAN L. LEONG, L.A. CARE HEALTH PLAN, E-PRESCRIBING
PILOT PROJECT 3 (2008), available at http://www.pharmacy.ca.gov/meetings/agendas/epre
scribing_pilot_project.pdf; “Medco Health Solutions Inc. and CalPERS (California Public
Employees Retirement System) have released results of a pilot electronic prescribing initiative
that showed dispensing rates for generic drugs were 11% higher for physicians who used such
technology.” Generics Use Rises with E-Prescribing, CHAIN DRUG REVIEW (Oct. 25, 2010),
http://findarticles.com/p/articles/mi_hb3007/is_18_32/ai_n56218400/.
140. ARIZ. ADMIN. CODE § R4-23-407(F)(2) (2009).
141. UTAH CODE ANN. § 58-82-201(1) (2010).
142. Id.
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eligible to receive electronic prescriptions.143
The law preemptively
accommodates the DEA rule by mandating that a practitioner may not eprescribe a drug or device that is prohibited by federal law or federal
rule.144
States like Arizona, Utah, and California145 now are only waiting on the
proper, secure hardware and software for the two-factor authentication
methods to be implemented at the prescriber level.146 The DEA along with
several technology stake-holders147 are issuing studies and pilot programs to
take the DEA regulation and put into practice appropriate, verification
technology.148 To comply with technology requirements of the DEA
regulation:
The application provider must either hire a qualified third party to audit the
application or have the application reviewed and certified by an approved
certification body. The auditor or certification body will issue a report that
states whether the application complies with DEA’s requirements and
whether there are any limitations on its use for controlled substance
prescriptions.149

143. Id. § 58-82-201(3).
144. Id. § 58-82-201(2).
145. Other states are included in this list as well. Alabama has included administrative
language that states: “Prescriptions for controlled substances, whether scheduled pursuant to
state or federal law, are not authorized until the DEA has adopted applicable regulations, at
which time all prescriptions for controlled substances must comply with the provisions of any
such regulation or any later amendments or changes thereto.” ALA. ADMIN. CODE r. 680-X2-.32(1)(d) (2011).
146. See DEA eRx, supra note 39.
147. Id.; see also Knowledge Base: Physician/Prescribers, SURESCRIPTS (Mar. 31, 2010),
http://www.surescripts.com/support/knowledge-base/physiciansprescribers.aspx#3189
(SureScripts does not provide any technology, but rather helps pharmacies ensure their existing
medical software is properly certified to meet e-prescribing requirements); see also
ePrescribing of Controlled Substances, ADVANCEDMD, http://www.advancedmd.com/pro
ducts-solutions/eprescribing/eprescribing-controlled-substances/ (last visited Jan 2, 2012)
[hereinafter ADVANCEDMD] (offering software for e-prescribing systems that ensure DEA
compliance).
148. Electronic Prescriptions for Controlled Substances, 73 Fed. Reg. 36,722, 36,730
n.12 (Jun. 27, 2008) (to be codified at 21 C.F.R. pts. 1300, 1304, 1306, 1311). The DEA
has sent letters to all eligible stakeholders to permit e-prescribing of controlled substances
pending verification of secure software and internet hosting. Letter from Mark W. Caverly,
Chief, Liaison and Policy Section, Office of Diversion Control, Drug Enforcement
Administration, to Provider of Electronic Prescription Application(s) or Pharmacy Application(s),
available
at
http://www.deadiversion.usdoj.gov/ecomm/e_rx/epcs_app_provider_ltr.pdf.
Additionally, it is important to point out that e-prescribing for controlled substances is currently
allowed; however, the verification process for secured computer software is currently being
developed, ADVANCEDMD, supra note 147.
149. See DEA eRx, supra note 39.
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A third-party audit must be conducted before e-prescribing of controlled
substances are written by a prescriber or dispensed by a pharmacy.150
Thankfully for practitioners and pharmacies, the third-party audit applies to
the provider of the e-prescribing software, usually the intermediaries or
software architects.151 The audit itself maintains explicit technological
requirements that are beyond the scope of this article, but needless to say
the DEA takes the verification process seriously because external and
internal security of the system is one of the highest priorities of eprescribing.152
Unlike those states with flexible statutory language that seems to
coincide with the DEA regulation there are states that have confusing or
conflicting rules. State legislation is in constant flux.153 States seem to be
caught in a situation where their statutes conflict with the new DEA
regulation. In Iowa, the administrative code states:
A prescriber may initiate and authorize a prescription drug order utilizing a
computer or other electronic communication or recording device. The
prescription drug order shall contain all information required by Iowa Code
section 155A.27. The receiving pharmacist shall be responsible for
verifying the authenticity of an electronically transmitted prescription or of an
electronic signature as provided by rule 657—8.19(124,126,155A) or
21.3(124,155A).154

It goes further by stating and incorporating:
21.7(1) Controlled Substances. A prescription for a controlled substance
prepared pursuant to this rule may be transmitted to a pharmacy via
facsimile transmission.
21.7(2) Noncontrolled prescription drugs. A prescription for a
noncontrolled prescription drug prepared pursuant to this rule may be
transmitted to a pharmacy via computer-to-computer transmission as
provided in rule 21.8.155

150. Id.
151. The burden of proving security will fall to e-prescribing intermediaries such as
SureScripts, AllScripts, and other software vendors. Id.
152. See Electronic Prescriptions for Controlled Substances—Interim Final Rule with Request
for Comment Questions and Answers for Pharmacies, DRUG ENFORCEMENT ADMIN. (Mar. 31,
2010), http://www.deadiversion.usdoj.gov/ecomm/e_rx/faq/pharmacies.htm (“The audits
must undergo either a WebTrust, SysTrust, or SAS 70 audit conducted by a person qualified to
conduct such an audit.” Alternatively an audit may be done by “a Certified Information
System Auditor who performs compliance audits as a regular ongoing business activity or a
DEA approved entity.”).
153. Todd, supra note 124, at 17.
154. IOWA ADMIN. CODE r. 657-21.7 (2009).
155. Id.
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This type of inconsistent language between the statute and the new DEA
regulation illustrates where the majority of states are situated. Much like the
Iowa Administrative Code, most state statutes and rules are less flexible and
cannot be read to interpret and then implement e-prescribing of controlled
substances.156 As seen in Rule 21.7(1) controlled substances may be
prepared via a facsimile but not via electronic transmission.157 This
inflexible language by the administrative code warrants change by Iowa
regulators.158 This change will come with little regulatory difficulty, but the
devil is in the details of the DEA regulation and state rule comparisons.159 If
a majority of states need to implement new language how will practitioners
and stakeholders know if language is consistent throughout each state?
Most attorneys and legislative aficionados can spot the inconsistency in this
language, but not all prescribers and pharmacists may focus in on
legislative nuances.
Many states after adoption of the DEA regulation will need new
legislation or rulemaking to provide for clear and concise standards for
prescribers, pharmacists, and regulators. These inconsistencies are not
reserved to a select few states but rather are the norm.160 Additionally, a
goal of these states should be to draft language that can be interpreted
liberally with flexibility to the ever-changing technology of medication
delivery.

156. Id.
157. Although CIII-CV prescriptions may be filled and written pursuant to a facsimile
prescription, CII prescriptions still require a paper prescription with the eligible DEA
prescriber’s hand written signature. Id. 657-10.21(1). CII narcotic prescriptions may also be
filled via facsimile under certain exceptions. Narcotics can be filled via facsimile for
emergency fills, id. 657-10.22(2) (2009), or for hospice or long-term care patients, id. 65710.23(2).
158. In a recent August 2011 update, the Iowa Board of Pharmacy proposed a change to
the administrative code, at IOWA ADMIN. CODE r. 657-21.7(1), which would amend the
regulation to: “A prescription for a controlled substance may be transmitted by a prescriber to
a pharmacy via electronic transmission pursuant to DEA [Drug Enforcement Administration]
requirements for electronic prescribing of controlled substances.” Update on e-Prescribing of
Controlled Substances, IOWA BOARD OF PHARMACY NEWS (Iowa Bd. of Pharmacy, Des Moines,
IA), Aug. 2011, at 5, available at http://www.nabp.net/publications/assets/IA082011.pdf.
Although this amendment to the Iowa regulations is comprehensive it does not expressly
address the DEA certification process, transmitting procedures by third party stakeholders, or
storage of electronic CII prescriptions. In addition, it is unknown at which time, and if, the
Board will adopt this amended proposal. However, this is a positive step in the direction of
the DEA rule and a streamlining of e-prescribing into current prescriber and pharmacy
workflow.
159. See id.
160. See, e.g., D.C. CODE § 48-903.08(a) (2011); FLA. STAT. § 893.04 (2010); GA.
COMP. R. & REGS. § 480-22-.04(1), (7) (2009).
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West Virginia is another state that has inconsistencies within its own
governing statutes and regulations:
“E-prescribing” means the transmission, using electronic media, of
prescription or prescription-related information between a practitioner,
pharmacist, pharmacy benefit manager or health plan as defined in 45
C.F.R. §160.103, either directly or through an electronic data intermediary.
E-prescribing includes, but is not limited to, two-way transmissions between
the point of care and the pharmacist. E-prescribing may also be referenced
by the terms “electronic prescription” or “electronic order” . . . .
. . . . A pharmacist may accept a prescription, including that for a controlled
substance listed in Schedules II through V, that is communicated in written
form or by E-prescribing. A pharmacist may accept a prescription, including
that for a controlled substance listed in Schedules III through V, and, in
certain situations, that for a controlled substance listed in Schedule II, that is
communicated orally (including telephone voice communication) or by way
of electronic transmission other than E-prescribing.161

Although the West Virginia rule seems to allow for e-prescribing of
controlled substances in the first sentence it may read to contradict itself in
the following sentence.162 This rule may be confusing, as e-prescribing for
controlled substances is currently prohibited in West Virginia pending DEA
technology certification and West Virginia’s approval.163 Adding to the
complexity, the West Virginia statute was recently amended to allow for eprescribing of controlled substances, in which the West Virginia Board of
Pharmacy states the statute is in concert with all other state and federal
authorities.164
Notwithstanding any other provision of this code to the contrary, Eprescribing, as defined in subdivision (15), section one-b of this article, is
hereby permitted and electronic prescriptions shall be treated as valid

161. W. VA. CODE R. § 15-1-2.1.18 (2009).
162. Id. § 15-1-21.1.1.
163. “At this time, prescriptions for controlled substances cannot be sent electronically and
must be written on tamper resistant prescription blanks for Medicaid patients. Hand-signed
hard copies of prescriptions for Schedule III through V drugs can be sent using manual fax
technologies. Be sure to follow DEA regulations and refrain from sending controlled
substance prescriptions electronically.”
WVeScript Online Learning: Frequently Asked
Questions, W. VA. BUREAU FOR MED. SERVICES, http://www.wvescript.com/frequently_asked_
questions (last visited Jan. 2, 2012).
164. E-Prescribing and Controlled Substances, FAQs from DEA, W. VA. BOARD OF
PHARMACY NEWS (W. Va. Bd. of Pharmacy, Charleston, W. Va.), Sept. 2010, at 1, available at
http://www.nabp.net/publications/assets/WV092010.pdf (citing W. VA. CODE § 30-5-12c
(2009)). Until recently, West Virginia was not situated to accept e-prescribing for controlled
substances, but in this newsletter article, the West Virginia Board of Pharmacy has addressed
the regulatory language and is convinced they are appropriately situated for a transition to eprescribing of controlled substances. Id.
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prescriptions orders. E-prescribing of controlled substances shall not be
permitted, except as provided by emergency rules promulgated by the
board . . . .
. . . . All electronic prescriptions shall be transmitted in a manner consistent
with applicable federal law, rules and regulations, including, but not limited
to, the Health Insurance Portability and Accountability Act of 1996, 29
U.S.C. § 1181, as amended, the Medicare Prescription Drug, Improvement
and Modernization Act of 2003, 42 U.S.C. § 1395w, as amended, the
Controlled Substances Act of 1970, 21 U.S.C. § 801, as amended, the
Drug Abuse Prevention, Treatment and Rehabilitation Act, 21 U.S.C. §
1101, as amended, and the Comprehensive Alcohol Abuse and Alcoholism
Prevention, Treatment and Rehabilitation Act of 1970, 42 U.S.C. § 4541,
as amended.165

It seems to the outside observer reading these statutes that West Virginia is
attempting to allow e-prescribing in section 30-5-12c(c); by allowing the
state to apply all applicable federal language.166 However, section 30-512c(1) makes it clear that e-prescribing of controlled substances is not
allowed in West Virginia until there is promulgation of emergency rules.167
The spirit of these two statutes seems to be in direct contradiction. The West
Virginia Board of Pharmacy states their rules and statutes are in compliance
with the new DEA regulation, which they seem to be.168 However, with the
implementation of technology standards by the DEA, West Virginia will have
to promulgate separate emergency rulemaking procedures to exercise eprescribing of controlled substances.169 In situations like this, hurried and
jumbled language has caused practitioners and pharmacists to give pause
when considering regulatory inconsistencies surrounding e-prescribing of
controlled substances.170 Specifically, the timing of e-prescribing
implementation is unsettled because practitioners will have to wait for

165. W. VA. CODE § 30-5-12c (2009).
166. See id.
167. See id. § 30-5-12c(a).
168. Id. § 30-5-12c(c). It is also important to note that West Virginia does have several
laws on the books that take into account privacy, security, and other issues that relate to the
barriers and fears of e-prescribing. See W. VA. CODE R. § 15-1-21.1.8.b (2011). It seems
the West Virginia Board of Pharmacy and legislature were extremely prospective in their
flexible language to comply with all of the pertinent integrity, privacy and security measures at
the state and federal level. Id.
169. See W. VA. CODE § 30-5-12c(a) (2009).
170. Confusing laws always seem to limit or at least make practitioners think twice about
moving to a given state. Chris Dimick, Fear Factor: Ambiguities in State Law Leave Some
Providers Hesitant to Adopt EHRs, J. AHIMA, Nov.-Dec. 2009, at 50, 50; see also Jonathan
Gill, Tough Laws, High Insurance Drive Doctors Away from West Virginia, L.A. TIMES, Jan. 7,
1990, at A10.
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emergency rules.171 Even when the CII prescription is allowed e-prescribing
status, West Virginia prescribers and pharmacists receive no benefit from the
practice because the subsequent regulation requires a paper prescription for
all CII medications.172 Currently:
If a CII prescription is given over the phone or via e-prescribing in an
emergency situation which is allowed, “the orally communicated prescription
is immediately reduced to writing by the pharmacist, or, if necessary, the
prescription communicated by way of electronic transmission is immediately
reduced to a hard copy.”173

The contradictions within West Virginia’s statutes and rules seem to
mean that a prescriber can send a CII prescription via e-prescribing, but the
electronic prescription must be reduced to writing. This negates many of the
potential workflow efficiencies, paper-less benefits, and potential security
measures offered by e-prescribing.174
The West Virginia legislative and regulatory confusion brings to light an
obvious but overlooked sentiment by states: the need to protect from
prescription drug diversion.175 The DEA addressed this in the background of
the rule and within their response to rule commentators.176 The DEA
reasoned e-prescribing would likely cut down on diversion by patients and

171. See W. VA. CODE § 30-5-12c(a).
172. W. VA. CODE R. § 15-1-21.1.6.
173. Id. § 15-1-21.1.6.b.
174. EHEALTH INITIATIVE, supra note 10, at 2-3; Jason Harris, Going Paperless: EHRs Offer
Challenges, Benefits, HEMONCTODAY (Aug. 10, 2010), http://www.hemonctoday.com/arti
cle.aspx?rid=67420. Ultimately the paperless system will enhance cohesive health delivery,
create a “greener” health care environment, and increase portability of medical records. See
Mark Singh, Benefits of Paperless Record Systems in Hospitals, CLINICORE HEALTH SOLUTIONS
(Apr. 8, 2010, 6:28 PM), http://clinicore.blogspot.com/2010/04/benefits-of-paperlessrecord-systems-in.html.
175. Prescription drug diversion is the deflection of prescription drugs from medical
sources into the illegal market. PILAR KRAMAN, COUNCIL OF STATE GOV’TS, DRUG ABUSE IN
AMERICA—PRESCRIPTION DRUG DIVERSION 4 (2004) available at http://www.csg.org/knowledge
center/docs/TA0404DrugDiversion.pdf. West Virginia’s laws have been established to reduce
oral and electronic prescriptions to writing and to confirm those prescriptions with a hard-copy
from the prescriber to prevent diversion. W. VA. CODE R. § 15-1-21.1.2 (2011). The
American Pharmacists Association (APhA) has expressed the sentiment that there is an
increased security benefit of e-prescribing to reduce forgeries of prescriptions for controlled
substance because e-prescribing patients will not have an opportunity to manipulate a paper
prescription. Electronic Prescribing of Controlled Substances: Addressing Health Care Law and
Enforcement Policies: Hearing Before the S. Comm. on the Judiciary, 110th Cong. 2 (2007)
[hereinafter APhA’s Senate Statement] (statement of The American Pharmacists Association
(APhA)).
176. See Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. 16,236,
16,244-45 (proposed Mar. 31, 2010) (to be codified 21 C.F.R. at pts. 1300, 1304, 1306,
1311).
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those outside of the health delivery model.177 By not allowing patients to
have physical contact with the prescription, when taking it from the
prescriber to the pharmacy, there is less chance for the document to be
tampered,178 altered or copied for the purpose of abuse.179 However, the
risk for internal diversion and diversion through technological means is still
of great concern.180 There is an increased risk of computer hacking or
manipulation of data through the technology intermediaries that manage
the e-prescribing software.181
The two-factor authentication is the DEA’s answer to internal diversion
issues. Although this will deter agents in a prescriber’s office or hospital
from forging controlled substance prescriptions, states and experts alike are
skeptical.182 Many times computer consoles stay logged-in allowing a
prescriber easy access, but this opens up an opportunity for potential
abuse.183 There may also be opportunities for an office employee to
observe a physician entering a password to use later for diversion purposes,
a two-factor authentication should limit this problem.184 Additionally, these
same security pundits find cause for concern about the security of the
network itself, through hacking.185 Could an enterprising computer expert
or hacker gain access to an e-prescribing system and then write
prescriptions that look legitimate? The answer may be yes.186 There are

177. Id.; APhA’s Senate Statement, supra note 175, at 2; Barlas, supra note 127, at 626.
Diversion of controlled substances is “a relatively simple task in the current paper-based
environment.” Kathryn Foxhall, HHS, DEA Still at Odds Over E-Prescribing, DRUG TOPICS
(Aug. 21 2006), http://drugtopics.modernmedicine.com/drugtopics/article/articleDetail.jsp?id
=365721.
178. See Electronic Prescribing of Controlled Substances: Addressing Health Care and Law
Enforcement Priorities: Hearing Before the S. Comm. on the Judiciary, 110th Cong. (2007)
(Statement of Joesph T. Rannazzisi, Deputy Assistant Director, Office of Diversion Control,
Drug Enforcement Administration), available at http://www.justice.gov/dea/pubs/cngrtest/ct
120407.html.
179. See Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. at 16,244.
180. Id. at 16,244-45.
181. See id. at 16,243; AM. COLL. OF PHYSICIANS, ELECTRONIC PRESCRIBING OF CONTROLLED
SUBSTANCES—A NEW OPTION 1, http://www.acponline.org/running_practice/technology/epre
scribing/dea.pdf.
182. Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. at 16,249-250.
183. Id. at 16,240.
184. Id. at 16,249.
185. Id. at 16,242.
186. See, e.g., Press Release, Drug Enforcement Administration, Statement for the
International Day Against Drug Abuse and Illicit Trafficking (June 27, 2008), http://www.jus
tice.gov/dea/pubs/pressrel/pr062708.html (“DEA Deputy Assistant Administrator for the
Office of Diversion Control, Joseph Rannazzisi, said ‘Our goal is to put in place an electronic
prescribing system that is efficient, medically beneficial to patients and prescribers, and
provides security from hackers and others who might seek to engage in fraudulent prescribing
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several e-prescribing technology intermediaries that facilitate the
transmission from the prescriber to the pharmacy.187 The DEA has
promulgated language that denotes any change to the content of a
prescription during transmission, including truncation or removal of data,
will render the electronic prescription invalid.188 As noted above, the DEA is
working on appropriate technological standards for e-prescribing and soon
a timeline and implementation of the technology will be outfitted for market
use.189 However, until that time states may see fit to prepare themselves for
the new technology through changes in their own statutes and regulations.
The DEA notes the two-factor authentication and additional computer
security measures will deter hacking.190 Also, prescribers are required to
print and observe monthly logs of their controlled substance prescriptions,
which encourage oversight and security.191 Computer software developers
have initiated a “hard-stop” in the e-prescribing software that would
automatically log-out a prescriber after a controlled substance prescription
is authorized.192 Additionally, the two-factor authentication is needed for
every controlled substance prescription.193 In actuality, internal diversion
can occur with or without e-prescribing software and it is up to prescribers,
insurance companies, and pharmacists to police the transmission of those
prescriptions.194 It can be argued that a stolen prescription pad from a
doctor’s office is just as dangerous as a breached e-prescribing system.195
Finally there is a third subset of states that have not adopted eprescribing of controlled substances language. The Nebraska Board of
Pharmacy has determined that until the DEA certifies the systems used by

activities.”); see also Jill Wechsler, Health IT Gains Momentum, MANAGED HEALTHCARE
EXECUTIVE (Jan. 1, 2008), http://managedhealthcareexecutive.modernmedicine.com/mhe/
News+Analysis/Health-IT-Gains-Momentum/ArticleStandard/Article/detail/482403. But see
CTR. FOR HEALTH TRANSFORMATION, supra note 40, at 12.
187. DEA eRx, supra note 39; MD. HEALTH CARE COMM’N, E-PRESCRIBING: AN INFORMATION
BRIEF 2-3 (2008), available at http://mhcc.maryland.gov/electronichealth/eprescribing/
PharmacyBoardReport062408v2.pdf. It is important to note that both SureScripts and RxHub
have never reported an incident of hacking or breach in their e-prescribing network. CTR. FOR
HEALTH TRANSFORMATION, supra note 40, at 12.
188. Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. at 16,288.
189. See supra text accompanying notes 200-06.
190. Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. at 16,242.
191. Id. at 16,262.
192. Ann Carrns, Special Health IT Report: Electronic Prescribing Increasing Despite
Glitches, KAISER HEALTH NEWS (June 29, 2009), http://www.kaiserhealthnews.org/Stories/
2009/June/29/eprescribe.aspx.
193. Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. at 16,249.
194. Id. at 16,261.
195. ELECTRONIC PRESCRIBING INITIATIVE, EHEALTH INITIATIVE, ELECTRONIC PRESCRIBING:
TOWARD MAXIMUM VALUE AND RAPID ADOPTION 73 (2004).
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prescribers and pharmacies.196 Nebraska will follow current law, not
change laws on the books and not allow e-prescribing for controlled
substances.197 The Nebraska statute currently reads:
[A] controlled substance listed in Schedule II of section 28-405 shall not be
dispensed without the written prescription bearing the signature of a
practitioner authorized to prescribe . . . .
. . . . Except as otherwise provided in this subsection or when administered
directly by a practitioner to an ultimate user, a controlled substance listed in
Schedule III, IV, or V of section 28-405 shall not be dispensed without a
written or oral medical order.198

Nebraska’s Board of Pharmacy’s software concerns illustrate certain
privacy issues.199 Additionally, the Nebraska Board of Pharmacy has
expressed the use of intermediaries is not ideal, and intermediary services
(also known as a “switch”) burden providers and pharmacists with extra
costs and security issues.200
Privacy concerns fall primarily under HIPAA201 through standards
imposed on the prescriber, pharmacy, and other business entities involved in

196. The Board requested that staff gather more information from the DEA before changes
to Nebraska statutes and regulations are pursued. The Board mentioned having discussions
with the Department regarding changes that may need to be made to the Uniform Controlled
Substances Act to allow electronic prescribing in Nebraska. NEB. BD. PHARMACY, MEETING
MINUTES MAY 10, 2010, at 2 (2010), available at http://dhhs.ne.gov/publichealth/Docu
ments/051010pharmminutes.pdf.
197. Id.; see also NEB. BD. PHARMACY, MEETING MINUTES JULY 12, 2010, at 4 (2010),
available at http://dhhs.ne.gov/publichealth/Documents/071210pharmminutes.pdf. It is
important to note that Nebraska pharmacy leaders are not against e-prescribing of controlled
substances, the Board of Pharmacy is simply skeptical about the certification process and
functionality of the security features of the e-prescribing systems. See EHEALTH COUNCIL, NEB.
INFO. TECH. COMM’N, E-PRESCRIBING WORK GROUP REPORT AND RECOMMENDATIONS 5-6
(2009), available at http://www.nitc.nebraska.gov/eHc/plan/reports/EprescribingRecommend
ations.pdf.
198. NEB. REV. STAT. § 28-414(2)(a) (2009).
199. See Gilman & Cooper, supra note 5, at 283-84; Sarah Rubenstein, Privacy
Advocates Sound Alarm About Electronic Prescribing WALL ST. J. HEALTH BLOG (July 29, 2008,
9:02 AM), http://blogs.wsj.com/health/2008/07/29/privacy-advocates-sound-alarm-aboutelectronic-prescribing/; see generally EPRESCRIBING DATA USE TASK GRP., EPRESCRIBING DATA
USE PROBLEM STATEMENT 4-5 (2009) (discussing various issues surrounding privacy and eprescribing).
200. EHEALTH COUNCIL, supra note 197, at 4.
201. See Health Insurance Portability and Accountability Act (HIPAA) of 1996 Pub. L. 104191, § 264, 110 Stat. 2033, 2033-34 (codified as amended at 42 U.S.C. § 1320d-2).
“HIPAA privacy and security standards still exert influence over several aspects of the
prescribing process, including storage of and access to related records, as well as the
communication of records between providers.” Greenberg et al., supra note 111, at 463.
“The kind of system integration and data sharing that offers greatest promise for improving
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electronic health care information.202 Providers and pharmacies have
adapted to HIPAA standards well but at a significant cost,203 which may lead
e-prescribing users with an impression that they will be able to adapt quickly
to any privacy concerns. However, state privacy laws may impede the
adoption of the e-prescribing process too.204 E-prescribing and EHR
systems will ideally allow the free flow of patient data to all parties that
require the electronic medical information.205 With data becoming more
accessible the danger is that more privacy violations under HIPAA or state
privacy law may appear.206
It seems these concerns may be over-emphasized. With the
computerization of patient health information (“PHI”) health care entities
have been able to adequately adapt and change their operations to meet
both state and federal laws.207 But if necessary, could EHR and e-

clinical prescribing practice is also the most challenging aspect of e-Rx under HIPAA and the
privacy regulations.” Id. at 465.
202. Greenberg et al., supra note 111, at 465.
203. Id. at 463.
204. “The ultimate goal [is]…to obtain appropriate privacy protections while facilitating the
development of fully functional, network-based e-Rx systems. Achieving this goal also could
involve some marginal tailoring of federal pre-emption of state privacy laws.” Id. at 467.
States may have a multitude of different privacy regulations concerning the medical
community; Iowa for example released a report discussing HIPAA preemption and Iowa
Privacy laws. See IOWA HIPPA SNIP, IOWA HIPAA PREEMPTION ANALYSIS: A REPORT ON THE
RELATIONSHIP BETWEEN HIPAA’S PRIVACY RULE AND IOWA STATUTORY LAW vi (2003), available at
http://www.iowamedical.org/documents/legal/IowaHIPAAPreemptionAnalysis.pdf. The HIPAA
preemption and individual state laws are beyond the scope of this article but it will be
important for states to address privacy laws as a possible barrier to e-prescribing adoption.
Greenberg et al., supra note 111, at 465-66.
205. “An interoperable system of HIE [health information exchange]—that is, one in which
various parties can share and exchange data among them—will have difficulty
accommodating the current range of variation in policy requirements.” Linda Dimitropoulos &
Stephanie Rizk, A State-Based Approach to Privacy and Security for Interoperable Health
Information Exchange, 28 HEALTH AFF. 428, 428-29 (2009).
206. An excellent resource to delve into the privacy concerns of EHR and e-prescribing is
RTI International and their work with National Health Information Security and Privacy
Collaboration (HISPC). See Press Release, RTI Int’l, RTI International to Support National
Health Information Security and Privacy Collaboration (Oct. 12, 2005), http://www.rti.org/
page.cfm?objectid=0AD0F1AC-B38F-4286-92481FDE5E224511. RTI International has
contracted with 34 states to investigate and consolidate privacy laws in states that serve as
barriers to EHR, Health Information Exchange (HIE), and e-prescribing adoption. LINDA L.
DIMITROPOULOS, PRIVACY AND SECURITY SOLUTIONS FOR INTEROPERABLE HEALTH INFORMATION
EXCHANGE—IMPACT ANALYSIS 3-2 (2007), available at http://www.rti.org/pubs/phase2_impact
analy.pdf; see also Greenberg et al., supra note 111, at 462.
207. Greenberg et al., supra note 111, at 462. Surescript’s statistics note an 181%
increase in e-prescribing and over 25% of all office based physicians are e-prescribing.
SURESCRIPTS, supra note 27, at 8, 10.
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prescribing laws provide a more comprehensive, uniform approach to
assessing privacy issues? Too heavy a burden is being placed on national
health care entities to adhere to a multitude of different state regulations.
With the exchange of information becoming a national endeavor208 and
health care entities stretching through all fifty states,209 there must be a
growing trend for states to consolidate uniform standards for e-prescribing
and privacy. New, flexible regulations or statutes must be entertained if not
adopted.
The inconsistent regulatory scheme nationwide remains a significant
barrier to e-prescribing for controlled substance adoption. As mentioned
above, technology pilot studies and tests are ongoing and will soon be
mimicked to allow for a full functioning, secure e-prescribing system.210
One of the few remaining barriers to e-prescribing is the passive resistance
of state statutes and regulations. The inconsistent language provided by the
majority of the states leaves practitioners, pharmacists, and technology
intermediaries waiting for state legislative action. There needs to be a
conscious and focused effort to implement regulatory amendments to
accelerate this slow adopting but extremely beneficial health delivery tool.
With only the technological barriers of DEA certification remaining, state
regulatory language is one of the final barriers e-prescribing advocates must
tear down.
V. IS MODEL LANGUAGE A SOLUTION?
Adoption rates of e-prescribing are growing211 but considering the
federal, state, and private initiatives212 already in place, it is argued that the
adoption rates of e-prescribing remain sluggish.213 Model language could

208. See Gilman & Cooper, supra note 5, at 287; SURESCRIPTS, supra note 27, at 11.
209. See NAT’L GOVERNORS ASS’N, supra note 10, at 5; Press Release, Walgreens,
Electronic Prescriptions Soar at Walgreens (Apr. 13, 2009), http://news.walgreens.com/arti
cle_print.cfm?article_id=5176; Press Release, CVS Caremark, CVS Caremark Announces ePrescribing Agreement with Allscripts (Jan. 7, 2010), http://investor.cvs.com/phoenix.zhtml?c
=99533&p=irol-newsArticle&ID=1372549&highlight=.
210. DEA eRx, supra note 39; see also AGENCY FOR HEALTHCARE RESEARCH & QUALITY,
AHRQ PUBL’N NO. 07-0047-EF, FINDINGS FROM THE EVALUATION OF E-PRESCRIBING PILOT SITES
v (2007), http://healthit.ahrq.gov/portal/server.pt/gateway/PTARGS_0_8969_227460_0_0_
18/Findings%20From%20The%20Evaluation%20of%20E-Prescribing%20Pilot%20Sites.pdf.
211. See SURESCRIPTS, supra note 27, at 10-11.
212. See, e.g., eRx Incentives, supra note 32; CTR. FOR HEALTH TRANSFORMATION, supra
note 40, at 16-24; CMS ePrescribing Incentive Program, AM. MED. ASS’N, http://www.amaassn.org/ama/pub/physician-resources/health-information-technology/incentiveprograms/cms-eprescribing-incentive-program.page.
213. JOY M. GROSSMAN, CTR. FOR STUDYING HEALTH SYS. CHANGE, ISSUE BRIEF NO. 133,
EVEN WHEN PHYSICIANS ADOPT E-PRESCRIBING, USE OF ADVANCED FEATURES LAGS 1 (2010),
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be the key to clarifying and quashing many of the barriers e-prescribing
needs to overcome.214 Significant merit must be given to the DEA rule and
other e-prescribing initiatives that have spent years on analysis and
implementation of e-prescribing standards. But DEA rules may not address
many of the state regulatory concerns that plague e-prescribing
implementation.215
Historically, model language has been created and used by state
legislatures and agencies to foster change in the regulatory scheme.216
Model language has been a successful tool throughout the legal community
for many years,217 for example model language has been drafted for use in
the health law sector,218 electronic transactions,219 and business code in
state law.220 E-prescribing model language may allow for a uniform
transition from old state rules to newer and more current forms of rules. It
could provide uniformity to all of the stakeholders of e-prescribing from the
practitioners, to regulators and third-parties.

available at http://www.hschange.com/CONTENT/1133/1133.pdf; see also Nathan, supra
note 54 at 203.
214. “The work of the ULC simplifies the legal life of businesses and individuals by
providing rules and procedures that are consistent from state to state—a consideration that
has become more critical as new technology wears away geographical borders and matters of
law implicate more than one state.” Frequently Asked Questions, NAT’L CONF. OF
COMMISSIONERS ON UNIFORM STATE LAW, http://www.nccusl.org/Narrative.aspx?title=Frequent
ly%20Asked%20Questions (last visited Jan. 3, 2012) [hereinafter NCCUSL].
215. The DEA rule seems to be silent on state privacy laws, state anti-kickback legislation,
and separate state licensure of prescribers and pharmacies. See Electronic Prescriptions for
Controlled Substances, 75 Fed. Reg. 16,236 (proposed Mar. 31, 2010) (to be codified 21
C.F.R. at pts. 1300, 1304, 1306, 1311).
216. See NCCUSL, supra note 214 (stating “[s]ince the ULC first convened in 1892, it has
produced more than 250 uniform acts focusing on such areas as commercial law, family or
domestic relations law, estates, probate and trusts, real estate, implementation of full faith and
credit, interstate enforcement of judgments, and alternate dispute resolution”).
217. See id.; see also ALI Overview, AM. L. INST., http://www.ali.org/index.cfm?fuseaction
=about.overview (last visited Jan 3, 2012); CORNELL UNIV. L. SCHOOL, Uniform Commercial
Code Locator: Uniform Law, LEGAL INFO. INSTITUTE, http://www.law.cornell.edu/uniform/
uniform.html (last visited Jan. 3, 2012). One author even goes so far as to entertain
uniformity of the prescriber’s licensing process. Daniel J. Gilman, Physician Licensure and
Telemedicine: Some Competitive Issues Raised by the Prospective of Practicing Globally While
Regulating Locally, 14 J. HEALTH CARE L. & POL’Y 87, 114 (2011).
218. See, e.g., UNIF. HEALTH-CARE INFO. ACT § 1-102 (1986), available at http://www.law.
upenn.edu/bll/archives/ulc/fnact99/1980s/uhcia85.pdf (providing an example of model
language in the health law sector).
219. See, e.g., UNIF. ELEC. TRANSACTIONS ACT § 2 (1999), available at http://www.law.u
penn.edu/bll/archives/ulc/fnact99/1990s/ueta99.pdf (providing an example of model
language in electronic transactions).
220. See NAT’L CONF. OF COMM’RS ON UNIF. STATE LAW, UNIFORM COMMERCIAL CODE,
http://www.nccusl.org/Update/ActSearchResults.aspx (last visited February 1, 2011).
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Model language can also be a source of expertise;221 not all states have
the time and money to spend on legislative drafting and model language
can bring in nationally renowned experts to help implement language.222
Not to mention draft a flexible, forward-thinking uniform rule that would
accommodate changes in the legal and health delivery environments.223
Model language takes the burden of drafting off of the states while allowing
them to implement either the whole or parts of a specific plan.224
On the other hand, one risk of model language use is that certain subsections of a state’s population would not be accommodated.225 Model
language “brushes with broad strokes” and as such may not be specific
enough for states with outlying population groups.226 Additionally, by virtue
of the drafting process interest groups will undoubtedly have input drafting
rules or statutes.227 This may create biases.228 Finally, model language may
take too long or be too involved. If the language is too cumbersome states
may choose not to adopt because they fear increased bureaucracy,
enforcement issues, or incidental cost.229
As illustrated above, states’ e-prescribing concerns include diversion and
privacy issues specifically in the realm of computer security and security at
the point of the prescriber. State boards of pharmacy or medicine may fear
they will be inundated with increases in diversion at the physician’s office
and the burden to investigate and protect against computer hacking—both
areas that have been traditionally beyond the scope of their regulating
expertise. Additionally, states may worry about anti-kickback legislation or
implications within their own fraud and abuse regulations. State language

221. Bruce H. Kobayashi & Larry E. Ribstein, The Non-Uniformity of Uniform Laws, 35 J.
CORP. L. 327, 328, 343 (2009) [hereinafter Non-Uniformity].
222. See Lawrence J. Bugge, Commercial Law, Federalism, and the Future, 17 DEL. J.
CORP. L. 11, 19 (1992); Larry E. Ribstein & Bruce H. Kobayashi, An Economic Analysis of
Uniform State Laws, 25 J. LEGAL STUD. 131, 140 (1996) [hereinafter Economic Analysis].
223. Bugge, supra note 222, at 18-19.
224. Non-Uniformity, supra note 222 at 330; Economic Analysis, supra note 222 at 140.
225. Economic Analysis, supra note 222, at 142.
226. Id.
227. “Interest groups can influence uniform law drafters even if these drafters are
appointed on a nonpolitical basis rather than elected . . . . [Uniform law makers] invite[]
‘advisers’ representing the groups to attend and participate in drafting and annual meetings.
Advisers can most influence those commissioners who lack independent knowledge that would
enable them to take positions that are not advocated at the meetings.” Id. Although it would
seem special interest groups are a “necessary evil” to get buy-in and appropriate expertise
involved in the drafting process. See Kathleen Patchel, Interest Group Politics, Federalism and
the Uniform Laws Process: Some Lessons From the Uniform Commercial Code, 78 MINN. L.
REV. 83, 100 (1993).
228. Economic Analysis, supra note 222, at 143.
229. See generally Economic Analysis, supra note 222, at 135-37.
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should be consistent. Rules and statutes need to align and guidance by
boards of pharmacy, medicine and nursing need to be clear.
Model language has the ability to address specific concerns and resolve
state privacy barriers, security issues, and inconsistent language. Sections of
model language should explicitly address each of these issues while taking
into account that some states may not adopt a given section. If this occurs,
model language would not only have to stand as a cohesive work but each
section should be well-drafted to stand on its own. An organization of
model language may look like this (including but not limited to the following
sections):
1)

Model Act for E-prescribing
a) §1 Definitions
i) Electronic Prescribing
ii) Electronic Transmission
iii) Prescription
iv) Valid Signature
v) Valid, eligible Prescriber
vi) Eligible Pharmacy (Resident or Non-Resident)
vii) Eligible Third Party Intermediaries
b) §2 Requirements of an Electronic Prescription (e-prescription)
i) Eligible Prescribers and Agents of Prescribers
(1) DEA Licensure/Approval
(2) State Controlled Substance Licensure
ii) Eligible Pharmacies
(1) DEA Licensure
(2) State Licensure
iii) Eligible Software and Systems Management Stakeholders
(1) DEA and/or State approval
(2) Third party certification
(3) Certified Biometrics, Hard Token, Password Specifics
iv) Scope of Medication that may be prescribed
(1) CII-CV
(2) Address CI Research Issues
(3) May have the option to limit or line item certain medications
v) Information Required (Prescription and Label information)
(1) Patient Identifiers
(2) Drug Identifiers
(3) Prescriber Information
(4) Prescription Information (Refills, Quantity, Drug, Dose, etc. . .)
(5) Standardized drug nomenclature and instructions for use
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d)

e)

f)

g)

h)
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vi) Training
(1) Physicians
(2) Pharmacists
(3) Pharmacists Technician
vii) Software Uniformity
(1) Similar Alerts and Warnings
(2) Similar construction of the software
(3) Reasonable Safety Measures Implemented
(4) Standardized drug names and terms
viii) Requirements of written prescriptions removed. Paperless system
§3 Security Measures
i) Two-factor authentication
(1) Password
(2) Hard Token
(3) Biometrics
ii) Agent of Prescriber
(1) Can agents assist in prescriptions (only ministerial duties)
iii) Software and technology measures (ascertained/unascertained)
(1) Valid eSignature
(2) What is a signature
§4 Recordkeeping
i) Monthly Logs
ii) Maintaining Records
iii) Record storage
§5 Feedback Measures
i) Insurance, physician, and pharmacist’s feedback loop
ii) What are the required functions and connectivity that must be
incorporated
§6 Privacy Concerns, Safe Harbors, Tax Incentives
i) Addressing HIPAA and state privacy laws
ii) Access to data
iii) Verification and validation either through the DEA or other State
agency
iv) Modification and Amendments to State Anti-kickback laws
§7 Emergency Measures
i) Emergency prescription uses
ii) Long Term Care, Hospice
iii) Public Health emergencies
§8 Penalties and Remedies
i) Criminal Offense for diversion
ii) Inappropriate billing (fraud)
iii) Medical malpractice, tort issues
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Model language would need to address conflicting definitions while
leaving ambiguity for changing prescribing practices and innovative health
technology. For example, language should address but not limit the scope
of computer transmissions, PDA or mobile e-prescribing, and physician
agent transactions. Model language should encompass all forms of
prescribers, such as physicians, dentists, nurse practitioners, optometrists,
and pharmacists with collaborative practice agreements. To encompass all
of the ascertained and unascertained stakeholders, any type of model
language should be flexible to unforeseen changes in the healthcare
landscape; for example, the advent of new prescribing professionals.
Beyond the overall intention of proposed model language, the definitions,
terms, or technological assertions should be given specific meaning. For
example, the term “electronic transmission” has a different meaning in
Iowa230 than it does in West Virginia.231
When attempting to draft uniform laws, drafters must respect nonadoption by the states. Any uniform law must walk the fine line between allencompassing versus uselessly ambiguous language. Giving substantial
meaning to terms and language must be considered at all possible avenues.
There is a significant danger for model language to become unmanageable if states need to qualify or add statutory clauses. Ambiguous
model language would just require states to do more work to clarify, guide,
and coax stakeholders into implementing e-prescribing.
Model language could also encompass and override conflicting
regulations and state codes.232 Allowing state legislatures to pass a law that
removes conflicting regulations in their own state would add significant
consistency within a single state. If the model language were to gain
widespread adoption it would also benefit those health care entities that
reach beyond one or two states. Uniformity amongst the states could
increase e-prescribing transactions and increase companies reach from a
regional to a national level. Giving states the tools required to pass
comprehensive rules would allow clarification for state regulators,

230. IOWA ADMIN. CODE r. 657-21.1 (2009).
231. “‘E-prescribing’ means the transmission, using electronic media, of prescription or
prescription-related information between a practitioner, pharmacist, pharmacy benefit
manager or health plan as defined in 45 C.F.R. § 160.103, either directly or through an
electronic data intermediary.
E-prescribing includes, but is not limited to, two-way
transmissions between the point of care and the pharmacist. E-prescribing may also be
referenced by the terms ‘electronic prescription’ or ‘electronic order.’” W. VA. CODE R. § 151-2.1.18 (2009).
232. As illustrated in the West Virginia example above, where the statutes seem inconsistent
with each other and the Board of Pharmacy guidance seems to allow e-prescribing. W. VA.
CODE § 30-1-12c(a), (c) (2009).
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prescribers, management, and other shareholders in public and private
health care entities.
A proposed uniform law or regulation would reduce time and effort
needed by legislators and their aides.233 However, any proposed model
language should include wide discretion at the state’s agency level
(professional boards) to maintain and endorse state autonomy in the
delivery and regulation of health care. Maintaining the state’s traditional
power to regulate health care234 will keep intact the core principles between
federal and state authority.235 Additionally, it should be noted that model
language would be the jumping-off point of e-prescribing rules. States may
be in a better position to tailor any language to their needs after the basic
underpinnings of e-prescribing are adopted through a uniform law. If a
state requires additional protective measures the uniform law should not
discourage customization. However, it would behoove drafters to think of
issues and potential solutions prior to a state’s individual adoption of any
uniform law. Uniform law adoption is rarely universal. Many states will
change or alter certain clauses for the benefit of their specific situation, but if
model language can set base-line understandings and definitions it will have
assisted in e-prescribing adoption.
The next steps to increase the adoption of e-prescribing of controlled
substances should be to establish a taskforce with the all of the major
stakeholders at the drafting table (Appendix A). The taskforce should
include groups from payors, providers, patient groups, regulators, and other
third-party intermediaries with an emphasis on unbiased drafting that could
result in adoption by a majority of the states. Enlisting a taskforce of state
regulators, healthcare parties, and patient advocacy groups seems like a
monumental task. But so are the savings and benefits that e-prescribing can
bring the health care delivery system.
VI. CONCLUSION
States, private health care entities and providers will shoulder the burden
when it comes to implementation of e-prescribing on a large scale. Model
language or a set of standards may accommodate and encourage rapid
adoption of e-prescribing. Additionally model language resolves many
unaddressed issues including regulatory inconsistency, diversion and
privacy. With the implementation of model language much of the burden
233. Economic Analysis, supra note 222, at 140.
234. See, e.g., NAT’L GOVERNORS ASS’N, supra note 10, at 8-10 (illustrating the various eprescribing initiatives); see also Electronic Prescriptions for Controlled Substances, 75 Fed.
Reg. 16,236, 16,304 (proposed Mar. 31, 2010) (to be codified 21 C.F.R. at pts. 1300,
1304, 1306, 1311).
235. Electronic Prescriptions for Controlled Substances, 75 Fed. Reg. at 16,304.
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can be taken off of the state and given to stakeholders and those who are
affected by the implementation of e-prescribing.
E-prescribing has
enormous potential to save lives, money, and time so patients, providers,
and payors can benefit.
CHARLES S. HARTIG*
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APPENDIX A. LIST OF POTENTIAL STAKE HOLDERS
Providers
Pharmacy Chain Representatives (e.g. Walgreens, CVS, Wal-Mart)
Community Pharmacy Owners
Staff Pharmacists
Family Practice Physicians and Other Physician Groups
Internal Medicine Physicians
Hospitals
Small, Rural Hospitals
Long-Term Care Facilities
Nurses
Special Interest Groups
American Pharmacist Association
American Medical Association
National Association of Board of Pharmacy (representing State Board of
Pharmacy)
Institute of Medicine
National Association of Chain Drug Stores
National Community Pharmacists Association
American Hospital Association
Health Care Information and Management Systems Society
American Insurance Association
National Association of Insurance Commissioners
American Health Information Management Association
National Governors Association
National Rural Health Association
Third Party Payors and Intermediaries
Insurance Companies (Blue Cross Blue Shield, WellPoint)
SureScripts
AllScripts
Software Developers
Government Regulators
Center for Medicare and Medicaid Services
Drug Enforcement Administration
Office of the National Coordinator for Health Information Technology
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Patient Advocacy Groups
Patient Advocacy Foundation
American Association of Retired Persons
Privacy Rights Clearinghouse
Electronic Privacy Information Center
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